Working Toward Tetanus, Diptheria, Acellular Pertussis in Every Pregnancy: Protecting Our Most Vulnerable Population by Scott, Jessica
University of Northern Colorado
Scholarship & Creative Works @ Digital UNC
Capstones Student Research
12-2016
Working Toward Tetanus, Diptheria, Acellular
Pertussis in Every Pregnancy: Protecting Our Most
Vulnerable Population
Jessica Scott
Follow this and additional works at: https://digscholarship.unco.edu/capstones
This Text is brought to you for free and open access by the Student Research at Scholarship & Creative Works @ Digital UNC. It has been accepted for
inclusion in Capstones by an authorized administrator of Scholarship & Creative Works @ Digital UNC. For more information, please contact
Jane.Monson@unco.edu.
Recommended Citation
Scott, Jessica, "Working Toward Tetanus, Diptheria, Acellular Pertussis in Every Pregnancy: Protecting Our Most Vulnerable
Population" (2016). Capstones. 30.
https://digscholarship.unco.edu/capstones/30
UNIVERSITY OF NORTHEN COLORADO 
 
Greeley, Colorado 
 
Graduate School 
 
 
 
WORKING TOWARD TETANUS, DIPHTHERIA, ACELLULAR  
PERTUSSIS IN EVERY PREGNANCY: PROTECTING OUR  
MOST VULNERABLE POPULATION 
 
 
 
A Capstone Research Project Submitted in Partial Fulfillment 
of the Requirements of the Degree 
Doctor of Nursing Practice 
 
 
 
 
 
 
Jessica Scott  
 
 
 
 
College of Natural and Health Sciences 
School of Nursing 
Nursing Practice 
 
December 2016 
This Capstone Project by: Jessica Scott 
 
Entitled: Working Toward Tetanus, Diphtheria, Acellular Pertussis in Every Pregnancy: 
Protecting Our Most Vulnerable Population 
 
has been approved as meeting the requirement for the Degree of Doctor of Nursing 
Practice in the College of Natural and Health Sciences in the School of Nursing, Program 
of Nursing Practice 
 
 
Accepted by the Capstone Research Committee  
 
 
 
______________________________________________________ 
Jeanette McNeill, DrPh, RN, CNE, ANEF, Research Advisor 
 
 
 
_____________________________________________________ 
Kristin Schams, DNP, RN, CE, Co-Research Advisor 
 
 
 
_______________________________________________________ 
Dorothy Schulte, FNP-BC, Community Representative 
 
 
Accepted by the Graduate School 
  
 
_________________________________________________________ 
Linda L. Black, Ed.D. 
Associate Provost and Dean 
Graduate School and International Admissions 
 
 
iii 
 
 
 
 
 
 
EXECUTIVE SUMMARY 
 
 
Scott, Jessica. Working Toward Tetanus, Diphtheria, Acellular Pertussis in Every 
Pregnancy: Protecting Our Most Vulnerable Population. Unpublished Doctor of 
Nursing Practice capstone project, University of Northern Colorado, 2016. 
 
 Pertussis is a highly contagious, acute respiratory illness caused by the bacteria 
Bordetella pertussis.  This illness can last for several months and is most notable by a 
paroxysmal cough on inspiration.  Pertussis affects all ages and genders without 
discrimination but has a disproportionately high rate of morbidity and mortality in infants 
less than three months old.  Protection from pertussis comes in the form of the tetanus, 
diphtheria, acellular pertussis (Tdap) vaccine for adults and the diphtheria, tetanus, 
acellular pertussis (DTaP) vaccine for children and infants.   
The first whole cell pertussis vaccine was introduced in the 1940s, which brought 
about a dramatic decrease in pertussis rates.  This vaccine was associated with high 
fevers and seizures in children.  This version of the vaccine was removed from the market 
in the 1980s and a safer acellular alternative was introduced.  The acellular vaccine had 
fewer side effects; however, immunity was noted to wane and pertussis incidence began 
to increase.  Infants who did not receive their first dose of Tdap until two months of age 
were left vulnerable after exposure to adolescents and adults with pertussis.  In October 
2012, the Centers for Disease Control (CDC; 2013b), in conjunction with the American 
Council for Immunization Practices (ACIP), released a national recommendation to 
provide every pregnant woman with a Tdap vaccine between 27- and 36-weeks gestation. 
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Vaccination during pregnancy would induce an immune response, creating antibodies 
passed on to the fetus.     
The purpose of this project was to improve the rates of Tdap in the pregnant 
population at North Colorado Family Medicine (NCFM) in Greeley, Colorado.  The 
project included three specific interventions: (a) update of an existing provider reminder 
tool located in every obstetric patients chart to include a prompt to give the Tdap vaccine 
between 27 and 36 weeks, (b) inclusion of a patient-oriented CDC (2015c) factsheet in 
the new patient packet given to every pregnant patient at the initial intake visit, and (c) an 
educational session provided to the clinic’s medical assistants to offer education on the 
purpose of the Tdap during pregnancy and their role in administering the vaccine under 
the clinic’s standing order.   
This project was implemented over a 14-week intervention period and results 
were measured with comparison of pre- and post-intervention vaccine rates and 
provider/medical assistant surveys.  Pre-intervention rates were calculated after chart 
review of all pregnancy and delivery codes for 2013-2015 after the initial 
recommendation.  Prior to the intervention, a total of 394 women delivered and 274 of 
those women were given the vaccine (69%).  Post-intervention chart reviews showed a 
total of 74 pregnant women were seen in the intervention window and 65 of those women 
were given the vaccine (88%).  Post-intervention provider and medical assistant surveys 
were distributed with a return rate of 48% for providers and 75% for medical assistants.  
Survey results showed participating medical assistants and providers agreed or strongly 
agreed the interventions would be beneficial in reminding them to provide the Tdap 
vaccine to pregnant women between 27- and 36-weeks gestation.  Indirectly, an increase 
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in Tdap vaccination rates in pregnant women would likely decrease pertussis rates and, 
therefore, the morbidity and mortality in infants less than three months of age.  This 
project was sustainable with future implications in practice as it utilized up-to-date 
evidence in an effort to increase rates of adherence to national recommendations and 
reduce rates of pertussis in a vulnerable population.  As the clinic is part of a larger 
system, the interventions can be disseminated to the different Banner health clinics and 
have a wider impact on pregnant women throughout the western United States.  
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CHAPTER I 
 
 
PROBLEM STATEMENT 
 
 
Introduction 
 Historically, with the introduction of vaccines in the United States and around the 
world, there has been a decrease in the number and severity of deadly diseases.  Vaccines 
brought with them the eradication of small pox and polio, and near eradication of 
diseases such as measles, mumps, and rubella.  One disease, however, continues to 
plague countries around the world despite the ability to vaccinate: pertussis.  Pertussis has 
had many names over the years; it was first named in the middle-ages as the kink, a 
Scottish term for fit or paroxysm, or kindhoest from the German language meaning 
child’s cough (Cherry, 1996).  Cherry (1996) describes the history of pertussis; the first 
epidemic was reported in Paris, France in 1578.  The causative agent of pertussis was 
unknown until 1906 when the Bordetella pertussis bacteria was finally isolated (Cherry, 
1996).  Over the century, pertussis has been called the 100-day cough due to its longevity 
and whooping cough--so named from the classic inspiratory whooping noise made when 
the cough is most severe (Cherry, 1996).   
Prior to the introduction of the first pertussis vaccine in 1933, children were 
affected by pertussis more than any other age group (Nitsch-Osuch et al., 2015).  In this 
pre-vaccination era, immunity in adolescents and adults came from natural immunity 
gained from persistent exposure to the illness.  Mothers would then pass this natural 
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immunity gained from exposure to the disease to their infants through the transfer of 
maternal antibodies through the placenta (Nitsch-Osuch et al., 2015).  With the 
introduction of the whole-cell pertussis vaccine--diphtheria, tetanus, and pertussis (DTP), 
disease rates in children dropped and natural immunity that would protect adults and 
adolescents was reduced.  Childhood vaccines brought a significant decrease in the 
incidence of pertussis, thus decreasing the overall morbidity and mortality associated 
with this disease.   
With the decreased incidence of pertussis, the nation’s focus shifted from concern 
about the disease to concern about the vaccine.  Severe local reactions at the vaccine site 
and systemic reactions that included high fevers and seizures would bring about an anti-
vaccination movement that would eventually end the mainstream use of the DTP vaccine 
(Allen, 2013).  The DTP vaccine was replaced with a safer alternative: the DTaP--
diphtheria, tetanus, acellular pertussis.  This new vaccine was purified, including only 
killed pieces of the pertussis bacteria, and was introduced as a safer alternative that would 
continue to protect the world from pertussis without the side effects of the vaccine.  After 
a short time, researchers realized this new, safer vaccine had come at a great cost--the 
immunity did not last (Allen, 2013).  Adolescents and adults were left unprotected, 
marking the start of a rapid rise in pertussis that has persisted to present day.  So began 
the pertussis paradox: vaccine uptake increased with the safer acellular pertussis vaccine 
but the incidence of pertussis started to climb (Allen, 2013).   
 While adults and adolescents with waning immunity have the highest disease rate, 
infants less than three months of age are at the greatest risk.  Nitsch-Osuch et al. (2015) 
reported adults and older siblings are responsible for at least three-quarters of pertussis 
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infections in infants.  Infants cannot receive their first DTaP vaccine until two months of 
age; with their developing immune systems, infants have the highest morbidity and 
mortality associated with pertussis infection (Sawyer & Long, 2015).  With this grim 
realization, the Centers for Disease Control and Prevention (CDC) and Advisory 
Committee on Immunization Practices (ACIP) have tried different strategies focused on 
protecting infants from pertussis (CDC, 2014b).  The first of these strategies included a 
recommendation for a one time adult and adolescent booster of Tdap in 2005 to try and 
reduce the incidence in illness in the population believed to be responsible for the highest 
transmission to infants (CDC, 2014b).  Another recommendation was released in 2008 
for a one-time maternal immunization with Tdap in the immediate postpartum period 
with the goal of protecting the mother and thus protecting the infant with whom she 
would have the most contact (CDC, 2014b).  It was determined that only protecting the 
mother would not offer enough protection to the infant so a new strategy--providing a 
booster to any unvaccinated adults or adolescents who would have contact with infants--
was recommended in 2011 (CDC, 2014b).  While effective, this strategy called 
cocooning was not financially feasible on a grander scale and still left the infant without 
any immunity of his or her own. (CDC, 2014b) 
With emerging evidence of placental transfer of antibodies producing passive 
immunity in infants, maternal immunization during pregnancy was determined a key 
strategy to reduce the burden of pertussis in infants.  In 2012, the CDC and ACIP 
announced the recommendation to provide the Tdap vaccine to all pregnant women 
between 27- and 36-weeks gestation regardless of previous vaccine status (Nesin, Read, 
Koso-Thomas, Isaacs, & Meulen, 2015).  Despite the recommendation from the CDC and 
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ACIP as well as an increasing amount of evidence supporting the safety and efficacy of 
the Tdap during pregnancy, national vaccine rates remained low and the incidence of 
pertussis remained high.  The purpose of this quality improvement project was to find an 
effective means of increasing the uptake of the Tdap vaccine in pregnancy in the primary 
care setting.  This project addressed the following problem/patient/population, 
intervention, comparison, and outcome (PICO) question: In pregnant women 27-36 
weeks gestation, how does the implementation of an intervention bundle including patient 
educational material, medical assistant education on existing standing order, and an 
updated provider checklist with visual reminder tool compared with no change in current 
practice affect Tdap vaccination rates in a large, urban primary care clinic? 
Background 
 Pertussis is a highly contagious, acute respiratory disease caused by the bacteria 
Bordetella pertussis or B. pertussis (Yeh & Mink, 2016).  This disease is most notable by 
its paroxysmal cough that can lead to post-tussive emesis and is characterized by the 
“whooping” sound made on inspiration (Cornia & Lipsky, 2015).  Pertussis is a gram-
negative bacteria transmitted only between humans through respiratory secretions (Yeh & 
Mink, 2016).  It has a longer incubation period than most other viral respiratory 
infections, ranging from one to three weeks, in stark contrast to typical viral infections 
whose incubation period is usually only one to three days (Cornia & Lipsky, 2015).   
There are three stages of pertussis: catarrhal, paroxysmal, and convalescent.  Yeh 
and Mink (2016) described the catarrhal stage as the early stage of pertussis where the 
aerosolized droplets are most contagious and there is the highest risk for transmission.  
During this stage, the illness most resembles an upper respiratory infection with mild 
5 
 
cough, sneezing, watery eyes, and low-grade fever without the notable paroxysmal cough 
and inspiratory whooping.  It is assumed the similarities between the common cold and 
the catarrhal stage of pertussis are primarily the reason for the high rates of transmission 
from adults and adolescents to unprotected infants.  The catarrhal stage typically lasts 
between one and two weeks.  The paroxysmal stage is where the severity of illness 
increases and infants have the highest rates of mortality.  Yeh and Mink described this 
stage as distinctive--there are long periods of coughing without the ability to inspire, 
causing the infants to become cyanotic and appear apneic.  The paroxysmal stage is 
where there is the typical inspiratory whoop and post-tussive emesis with coughing 
spells.  Infants are more at risk for complications at this stage with reported cases of 
bradycardia, tachycardia, apnea, seizures, respiratory distress, respiratory failure, 
pneumonia, hypotension leading to shock, renal failure, and death (Yeh & Mink, 2016).  
This stage can last up to eight weeks where the paroxysmal cough worsens over the first 
couple of weeks, remains at a high intensity for two or three weeks, and then gradually 
lessens.  According to Yeh and Mink, the last stage, the convalescent stage, can last 
several weeks to months with symptoms gradually subsiding until resolved.   
Treatment for pertussis varies depending on the age of the individual.  Adults and 
adolescents can be treated with antibiotics and usually recover at home without any 
complications (Yeh, 2016).  Children greater than one year of age may require some 
more supportive therapy, such as fluid administration and nutritional support, but are 
rarely hospitalized (Yeh, 2016).  Infants less than six months old have a higher morbidity 
and mortality associated with pertussis and often require supportive therapy in the 
hospital setting.  Infants who are in respiratory distress will be admitted to the hospital for 
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supportive therapy where the diagnosis of pertussis is then established through clinical 
indications or polymerase-chain reaction assays (PCR).  Infants are placed in droplet 
isolation and have an intravenous catheter established for parenteral fluids and antibiotics 
(Yeh, 2016).  Supportive therapy is continued until the infant is able to tolerate 
paroxysmal coughing episodes without subsequent hypoxia requiring oxygen and is able 
to eat independently (Yeh, 2016).   
 Prior to the introduction of the vaccine, the highest incidence of pertussis in the 
United States occurred in 1934 with 250,000 reported cases (Cornia & Lipsky, 2015).  
The first vaccine came in 1933 when the pertussis bacteria, suspended in a phenolyzed 
saline, was introduced (Cherry, 1996).  Over the next decade, scientists tried different 
ways to create an effective vaccine.  Then in the early 1940s, the whole cell vaccine was 
introduced and a significant decrease was seen in the incidence of pertussis around the 
world (Cherry, 1996).  The whole cell organism was then combined with the tetanus and 
diphtheria vaccine and the first DTP vaccine was mass produced and widely distributed 
in developing countries.  Cornia and Lipsky (2015) reported the DTP vaccine saw high 
rates of localized and systemic reactions but by 1976, a disease that had once been 
responsible for millions of illnesses and hundreds of thousands of deaths had decreased 
dramatically in developing countries.  In the United States, with the DTP vaccine 
mainstreamed and widely used, the lowest reported incidence of pertussis in 1976 was 
just 1,010 cases (Cornia & Lipsky, 2015).   
The whole cell pertussis vaccine contained killed B.pertussis, diphtheria, and 
tetanus (Allen, 2013).  Side effects associated with the whole cell pertussis vaccine 
included high fevers and seizures, which started an anti-vaccine movement in the early 
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1980s and led to manufacturers being sued and pulling out of the vaccine market (Allen, 
2013).  During this anti-vaccine movement, studies were done showing no identifiable 
link between the vaccine and any permanent brain impairment but the damage to the 
public’s perception of the vaccine’s safety was done, compelling manufacturers to start 
looking at a safer version of pertussis immunization.  The new vaccine replaced the 
whole cell killed B. pertussis component with pieces of the bacteria that had been 
purified to remove any possible contributors to the side effects experienced with the 
whole cell vaccine (Allen, 2013).  Soon after the DTP vaccine was taken off the market 
and replaced with the diphtheria, tetanus, acellular Pertussis (DTaP) vaccine, it was 
discovered the side effects of the original DTP vaccine were from an endotoxin released 
from the bacteria’s cell membrane (Allen, 2013).  The newer DTaP quickly had the 
component associated with the endotoxin removed from the vaccine and became the new 
and widely used replacement of the whole cell vaccine.   
 Allen (2013) wrote that soon after the wide-spread use of the acellular vaccine, 
antibody responses to the vaccine were as high, if not higher than the whole cell vaccine, 
without the fevers and seizures that started the anti-vaccine movement in the 1980s.  All 
was well until data started to emerge about increasing incidences of pertussis in 
adolescents and young adults who had been among the first cohorts of children to receive 
the DTaP.  Cornia and Lipsky (2015) described how the emergence of pertussis in this 
age group led researchers to the conclusion that the newer, safer acellular pertussis 
vaccine had a waning immunity the whole cell pertussis vaccine did not have.  This 
waning immunity created a resurgence of pertussis in adolescents and adults with less 
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severe disease symptoms, was often mistaken for other respiratory illnesses, and led to 
unintended exposure to unprotected infants (Cornia & Lipsky, 2015).   
Significance 
 Trending data from the introduction of the acellular pertussis vaccine in the mid-
1990s showed a steady increase in pertussis rates in the United States.  The highest 
numbers were seen in the peak epidemic of 2012 with 48,277 cases of confirmed 
pertussis in all age groups.  Of the total cases reported that year, more than half were in 
adults and adolescents where immunity was believed to have waned from childhood 
vaccinations (CDC, 2013a).  There were 20 confirmed deaths from pertussis in 2012 and 
15 of those deaths were in infants less than three months old, accounting for 75% of the 
pertussis-related deaths that year (CDC, 2013a).  There were 13 total deaths from 
pertussis in 2013 and 12 of those deaths were in infants less than three months old, 
accounting for 92% of the pertussis-related deaths (CDC, 2014a).  In 2014, there were 13 
deaths related to pertussis and eight of those deaths were in infants less than three months 
old, accounting for 61% of the pertussis-related deaths that year (CDC, 2015a).  The 
burden of pertussis in infants is significantly higher than that of children, adolescents, and 
adults.  Infants with the disease have the highest rate of hospital admissions and carry the 
highest morbidity and mortality rate (Goldfarb, Little, Brown, & Riley, 2014).  The 2012 
pertussis epidemic raised new concerns for healthcare providers on how to more 
effectively protect this vulnerable population.   
Financial Impact 
 Pertussis illness brings with it a heavy economic burden.  The financial burden of 
pertussis can be measured in the cost of treatment and hospitalizations as well as loss of 
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productivity for those caring for the ill.  Even in countries that have implemented 
vaccination programs targeted at reducing pertussis illness, the persistence of the 
pertussis endemic remains a significant public health concern.  The true economic burden 
of pertussis is hard to measure as it is assumed this disease is widely underdiagnosed and 
underreported.  Greenberg and Caro (2005) offered some idea of the cost of pertussis on 
an individual level.  For infants younger than the age of two months, the estimated cost of 
pertussis disease was $2,822, which would increase with hospitalization and 
complications to as much as $6,337 per infant.  The authors also reminded the readers 
these costs were for direct care costs and did not include productivity and income lost 
when parents were missing work to care for their sick child (Greenberg & Caro, 2005).   
Caro et al. (2013) examined the true cost and burden of the pertussis illness.  This 
study found the highest direct medical costs of pertussis were in the infant population.  
The direct medical costs reported by Caro et al. were in line with those reported by 
Greenberg and Caro (2005) but this study expanded on the indirect costs of pertussis 
illness by lost days of work.  Caro et al. found the average number of days lost when 
caring for an ill family member with pertussis was six days of work with an estimated 
cost of $767 per family when caring for an ill family member at home and $1,025 per 
family when caring for a hospitalized infant.  
 O’Brien and Caro (2005) reported costs of pertussis hospitalizations by age group.  
Data were gathered from hospital discharge databases from 1,000 hospitals in four 
different U.S. states between 1996 and 1999.  The results of this study found infants less 
than one-year-old made up the majority of pertussis-related hospitalizations and those 
hospitalizations were costlier than the older cohorts.  The mean cost of an average six-
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day hospital stay for infants was $9,586 compared to a mean cost of $4,729 for 
adolescents and adults (O’Brien & Caro, 2005). 
 To determine whether or not a vaccine strategy would be cost effective, the first 
step has been to define the value of life.  This value in literature was often measured as 
quality adjusted life years (QALY), which is a method of assigning value to years of life 
gained through disease prevention and/or treatment.  Lugnér, van der Maas, van Boven, 
Mooi, and de Melker (2013) performed a cost-effective analysis by examining three 
different vaccine strategies in an effort to reducing the burden of pertussis illness on 
newborns and infants:  neonatal vaccination, maternal vaccination, and cocooning.  From 
strictly a monetary standpoint, this cost-effective analysis found cocooning was more 
cost-effective than the maternal vaccination strategy.  With regard to QALY gained, the 
maternal vaccine strategy found higher QALY gained for the maternal vaccination 
strategy (Lugnér et al., 2013).   
 Terranella, Asay, Messonnier, Clark, and Liang (2013) conducted a study using a 
cohort model that looked at all U.S. births in 2009 and analyzed cases of pertussis, 
hospitalizations, and deaths of infants less than one-year-old.  They also looked at the 
direct and indirect costs of pertussis illness in infants less than one year of age.  These 
numbers were analyzed to simulate the cost of maternal vaccination versus the post-
partum cocooning strategy and looked at cost-effectiveness and quality adjusted life year.  
The results of this study found maternal immunization reduced pertussis rates by 33% 
whereas postpartum vaccination reduced pertussis rates by 20%.  Hospitalizations were 
reduced by 38% with the maternal vaccination method and 19% by the postpartum 
method.  Deaths related to pertussis illness in infants less than one-year-old were reduced 
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by 49% in infants whose mothers received the Tdap vaccine during pregnancy compared 
with 19% whose mothers were vaccinated after pregnancy.  Cost was calculated based on 
QALY saved and was significantly lower for maternal immunization versus postpartum 
vaccination--$414,523 versus $1,172,825, respectively (Terranella et al., 2013).   
Improving Tetanus, Diphtheria, and Acellular Pertussis  
Immunization Rates Using the Reach, Efficacy,  
Adoption, Implementation, and Maintenance  
Framework 
 
 Introduced in 1999, the purpose of the reach, efficacy, adoption, implementation, 
and maintenance (RE-AIM) model was to give researchers a theoretical model to 
evaluate how well an intervention would reach and impact a community (Glasgow, Vogt, 
& Boles, 1999).  It seemed relevant that health promotion interventions in the public and 
community health settings were only as good as could be measured through effective 
evaluation.  A systematic review of the use of RE-AIM described the use of the 
framework from early and planning stages of an intervention, providing guidance 
throughout the process and a structured method for evaluation as valuable on the impact 
of public health and community-based initiatives (Gaglio, Shoup, & Glasgow, 2013).  
The purpose of RE-AIM is to determine the real-world applicability and viability through 
methodical and standardized assessment as a way to ensure generalizability and 
sustainability in the community and population (Virginia Tech, 2015).  By carefully 
reviewing the RE-AIM framework, Gaglio et al. (2013) described the most efficacious 
use of this model is when all five dimensions are discussed individually and 
comprehensively.   
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Reach   
Identification of a target population is among one of the first steps in initiating a 
community-based intervention.  The target population for this capstone intervention was 
pregnant women at a large, urban primary care and family medicine clinic in Greeley, 
Colorado.  This group was chosen because improving immunization rates for tetanus, 
diphtheria, and acellular pertussis (Tdap) during pregnancy would not only benefit the 
mother but had the end goal of preventing pertussis illnesses in her unborn child.  Reach, 
the first evaluation dimension in the RE-AIM network, determined what percentage of 
pregnant women targeted by this capstone would participate in the intervention.  Prior to 
initiation of this intervention bundle, it was estimated approximately 11% of the 
population at the target clinic were being seen for pregnancy-related health maintenance.  
The first goal was to reach 100% of the target population by providing every pregnant 
patient with educational material regarding the safety and efficacy of the Tdap during 
pregnancy at their initial intake visit.  It was determined the percentage of pregnant 
women who participated (received the vaccination) also depended on education provided 
to medical assistants and providers.  The optimal way to reach 100% of medical 
assistants was to attend two required monthly meetings and provide verbal education 
regarding an existing standing order to provide every pregnant patient between 27 and 36 
weeks with a Tdap booster.  To reach the providers, the intervention thought to have the 
most impact was to update an existing provider checklist that would be placed in every 
pregnant patient’s physical obstetrics chart.     
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Effectiveness 
The RE-AIM framework (Virginia Tech, 2015) defined an effective initiative or 
intervention as having a positive impact on the quality of life and health outcomes of 
individuals, communities, and populations.  The effectiveness of any intervention 
describes the end result at the individual level, i.e., the target population was reached and 
participated and there were positive outcomes (Glasgow et al., 1999).  The goal of this 
intervention was to increase Tdap rates in an effort to decrease the rates of pertussis in the 
infant population by offering passive immunity through the transference of maternal 
pertussis antibodies.  Pertussis does not discriminate.  It affects individuals of all ages, 
races, ethnicities, and cultures.  It does not target specific populations based on socio-
economic status, income levels, or educational levels.  Children, adolescents, and adults 
who are infected by B. Pertussis can be sick for weeks or even months but typically 
recover without any long-term sequela.  On the other hand, infants have a longer duration 
of illness, can have lengthy and costly hospitalizations, and have the single highest rate of 
mortality from pertussis (Cornia & Lipsky, 2015).  The effectiveness of this intervention 
bundle was intended to improve Tdap vaccination rates at the individual level, increase 
the likelihood of population-based generalizability, and to affect vaccine rates at a 
national and global level.  Preventing illness in newborns and infants through maternal 
vaccination will have a long term impact on the health outcomes of individuals, 
communities, and populations, as well as having a positive economic impact by reducing 
vaccine preventable illnesses that can lead to costly hospitalizations and death. 
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Adoption 
Adoption of the intervention bundle was measured at the organizational level 
through compliance of all clinic staff, medical assistants, and providers.  Adoption differs 
from reach in that it measures use and compliance in the setting and at community and 
population-based levels; reach looks only at the individual level.  Use of the Tdap 
vaccine during pregnancy has been well-researched and is backed at local, state, national, 
and global levels through widespread recommendations by the National Institutes of 
Health (NIH), Centers for Disease Control (CDC), American College of Obstetricians 
and Gynecologists (ACOG), World Health Organization (WHO), and various other 
institutions around the world (CDC, 2013b).  The plan for adopting this intervention was 
assessed through medical assistant and provider surveys.  The surveys assessed the 
effectiveness of the medical assistant educational sessions to evaluate the intervention as 
well as any barriers the medical assistants found when ordering and giving Tdap vaccines 
to pregnant patients.  The providers were also given a survey to assess the effectiveness 
of the provider reminder tool and CDC (2015c) pertussis factsheet as well as barriers and 
opportunities for improvement.   
Implementation   
Implementation is different from adoption and/or effectiveness in that it looks at 
how well or not a program was initiated as originally intended (Glasgow et al., 1999).  
Planas (2008) further described implementation as having intervention fidelity or holding 
true to/committing to implementing an intervention as planned and proposed.  The 
intervention for this capstone consisted of three quality improvement strategies 
implemented at the provider and medical assistant levels in an effort to increase 
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compliance and rates of Tdap during pregnancy.  The interventions are described in 
greater detail in Chapter III but in summary, they included an update to an existing 
provider reminder checklist in use prior to the intervention, two educational sessions for 
medical assistants regarding the use of an already existing standing order that included 
Tdap during pregnancy, and the inclusion of a CDC authored educational handout 
discussing the safety and efficacy of the vaccine during pregnancy in pre-existing patient 
education packets.  To maintain intervention fidelity, the same educational material was 
provided to all pregnant patients, the education provided to the medical assistants was 
done at the monthly meetings using the same educational PowerPoint, and the current 
checklist used by providers was updated to ensure each provider was given the same 
information.  The purpose of each intervention was to enhance practices already 
established in this clinic to improve the likelihood of maintenance. 
Maintenance 
Maintenance refers to long-term outcomes and sustainability at both the 
individual and organizational levels (Planas, 2008).  Maintenance of this quality 
improvement project at the individual level was reflected by increased compliance in 
receiving the vaccine at the right interval, which was intended to lead to a reduction in 
pertussis rates in northern Colorado.  Measuring maintenance at the individual level 
could only be completed by measuring compliance as measuring associations between 
the vaccine and decreased pertussis rates were out of the scope of this project.  
Maintenance at the organizational level was reflected in the increased rates of the Tdap 
vaccine given during pregnancy and was measured through retrospective chart review.  
Planas (2008) described several factors that influenced the long-term uptake and success 
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of an intervention.  The first factor described was the manner in which the site was 
initially approached with the intervention plan.  Interventions rooted in a research nature 
were determined to have a lower likelihood of long-term success as the participants often 
saw the interventions and results as short term.  Interventions such as this one, which was 
approached as quality improvement, were often viewed more as long term with a higher 
likelihood for adoption and compliance (Planas, 2008).  This intervention was meant to 
be long term as it was not a practice change but rather an update and improvement of 
interventions already in place.  This quality improvement project used key personnel who 
were already in place and described as being vital to successful implementation and 
maintenance (Planas, 2008).  The last factor described by Planas was the meaningfulness 
of the intervention to stakeholders.  Stakeholders in this intervention were pregnant 
women, medical assistants, and clinic providers.  This intervention was anticipated to be 
meaningful to the majority of pregnant women as this intervention provided optimal 
protection to newborn infants from pertussis.  Providers and medical assistants, with the 
understanding they were providing a meaningful service, were predicted to maintain this 
practice for the benefit of their individual patients, families, and communities.   
Project Objectives 
This intervention plan focused on providing resources and education to office 
providers including physicians, nurse practitioners, and medical assistants.  There were 
three primary objectives for the project: 
 Update and improve current practice to increase the rate of Tdap 
immunizations in pregnant women at North Colorado Family Medicine. 
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 Increase provider awareness and compliance with the national 
recommendations of providing every pregnant patient with a Tdap vaccine 
between 27- and 36-weeks gestation. 
 Increase medical assistant awareness and compliance with current standing 
order to administer all pregnant patients with Tdap vaccine. 
Intervention methods were implemented and evaluated based on these three primary 
objectives and are described in more detail in the methods section.   
Congruence of Intervention Plan with Organization’s  
Strategic Plan 
 North Colorado Family Medicine is part of a larger system (Banner Health) with 
clinics located in Arizona, Alaska, California, Colorado, Nebraska, Nevada, and 
Wyoming (Banner Health, 2016a).  Banner Health (2016a) considers itself one of the top 
nonprofit organizations in the country--their primary focus being to excel in their mission 
to make a difference in the lives of every person who interacts with the system.  Banner 
Health describes its strategic plan as providing the best care and health services to 
communities it serves rather than just focusing on generating profits.  By following this 
strategic model, Banner Health reinvests all of the money earned into updating 
technologies, attracting provider talent, paying employee salaries, and improving every 
clinic and hospital to the highest standards.  Banner Health (2016a) describes in their own 
words their mission, vision, and values: 
Mission.  To make a difference in people's lives through excellent patient care 
(para. 1). 
Vision. We will be a national leader recognized for clinical excellence and 
innovation, preferred for a highly coordinated patient experience, and 
distinguished by the quality of our people (para. 7). 
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This quality improvement project sought to align with the strategic plan, mission, 
and vision of Banner Health by providing the safest and most up-to-date care to pregnant 
women and their unborn children.  The Tdap in every pregnancy is a national initiative 
supported by research regarding the safety and efficacy of the vaccine and is a relatively 
low cost and easy initiative with long-lasting benefits (National Foundation for Infectious 
Diseases [NFID], 2014). 
Summary 
 Pertussis is a respiratory illness that is gravely dangerous to infants less than three 
months old.  There have been 35 reported deaths in infants less than three months old 
related to pertussis in the last three years in the United States (CDC, 2103a, 2014a, 
2015a).  Infants in this age range are highly susceptible to this illness because the first 
immunization protecting babies from pertussis is not given until two months of age, the 
full series is not completed until 12-18 months of age, and a booster shot is given 
between four and six years old (CDC, 2015c).  Adults, older children, and adolescents act 
as the primary source of infection to these newborns and young infants as the early 
symptoms in adults and adolescents often present as the common viral cold.  Vaccinating 
every mother with the Tdap vaccine during pregnancy offers passive immunity to the 
newborn for the first two months of life until the first Tdap vaccine can be safely 
administered (CDC, 2015b).  Care of the pregnant patient is done in many settings 
including obstetric offices, family care clinics, and hospital settings.  Vaccines are 
commonplace in most office settings and it is assumed the majority of providers are 
knowledgeable about the safety and efficacy of the Tdap vaccine.  Pregnant women rely 
on their providers to maintain the most up-to-date knowledge regarding the 
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recommendations, safety and efficacy of vaccines.  In following the most updated 
recommendations, providers have a responsibility to discuss the Tdap vaccine with every 
pregnant patient, reduce vaccine hesitancy with increased patient education during office 
visits, and then offer and administer the vaccine to every pregnant patient.   
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
 
A literature search was conducted using PubMed, CINAHL, Cochrane library, 
and Google Scholar.  The search was done using various combinations of the following 
key words and phrases: immunizations in pregnancy, Tdap in pregnancy, pertussis and 
pregnancy, safety of Tdap immunization in pregnancy, pregnancy outcomes and Tdap, 
immunizations and birth outcomes, immunogenicity of Tdap in pregnancy, vaccine 
hesitancy and pregnancy, Tdap vaccine uptake and pregnancy, vaccine perceptions and 
pregnancy, vaccination improvement strategies and Tdap, epidemiology and pertussis, 
and effectiveness of Tdap in pregnancy.  For the scope of this project, the entirety of 
literature regarding Tdap vaccines during pregnancy was not included and studies were 
chosen based on relevance to the current project.  The literature review parameters 
included only studies published in the last five years and all types of studies were 
included.  Studies from different countries were included based on relevance to the 
current project.  Studies were sorted into the following categories: vaccine safety, vaccine 
effectiveness, immunogenicity, vaccine hesitancy, and vaccine uptake improvement 
strategies.  
Vaccine Safety 
Five studies and one systematic review were included that assessed the safety of 
the Tdap vaccine in pregnancy.  Different outcomes measured included unspecified 
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adverse events, infant growth and development, small for gestational age (SGA), preterm 
birth, major malformations, chorioamnionitis, Apgar score, cord blood pH, hypertensive 
disorders in pregnancy, and spontaneous abortion and stillbirth rates.   
Kharbanda et al. (2014) measured different obstetric outcomes in mothers and any 
adverse events in newborns just after birth.  Specific events and outcomes measured were 
SGA births, chorioamnionitis, preterm birth, and hypertension in pregnancy.  This study 
was a retrospective, observational cohort study that measured the outcomes of 123,494 
women between 2010 and 2012.  Data for this study were pulled from the California 
Vaccine Safety Datalink database.  Of the 123,494 women studied, 26,229 received the 
Tdap vaccine during pregnancy.  No association was found between the Tdap vaccine 
and any adverse obstetric or birth outcomes.   
Kharbanda et al. (2016) measured adverse outcomes in a large observational study 
of women who received the Tdap vaccine between 2007 and 2013.  Specific outcomes 
included neurologic events, thrombotic events, new onset proteinuria, gestational 
diabetes, cardiac events, and thrombocytopenia.  Data were collected from the California 
Vaccine Safety Datalink.  No acute adverse events were measured in the cohort of 
women who received the vaccine during pregnancy.   
In a retrospective cohort study, Morgan et al. (2015) compared pregnancy 
outcomes among women who received Tdap during pregnancy, women who did not 
receive Tdap during pregnancy, and multiparous women who had received Tdap in a 
previous pregnancy within the last five years.  Outcomes measured were rate of 
stillbirths, major malformations, chorioamnionitis, five-minute Apgar score, and cord 
blood pH.  The study did not find any increase in adverse outcomes in the group that 
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received the Tdap vaccine during pregnancy; however, the study did find significantly 
increased rates of preterm birth and SGA births in the unvaccinated group.   
Munoz et al. (2014) conducted a phase 1-2, randomized, double-blind, placebo-
controlled clinical trial measuring outcomes in women who received the Tdap 
immunization between 2008 and 2012.  The primary outcomes looked for any adverse 
outcomes with receipt of the vaccine but were not specific.  The study also measured 
post-partum pertussis illness and the growth and development of the infant through the 
first 13 months of life.  There were no measurable adverse events after receipt of the 
Tdap vaccine during pregnancy and growth and development were similar in all groups.  
In a retrospective cohort study that looked at 138 women who had received the 
Tdap vaccine during pregnancy, Shakib et al. (2013) measured birth outcomes including 
rates of preterm births, spontaneous abortions, and SGA births.  This study found no 
increased risk for preterm birth, spontaneous abortion, and SGA birth for women who 
had received the Tdap vaccine during pregnancy. 
One systematic review included in this literature review related to the safety of 
the Tdap vaccine during pregancy.  Keller-Stanislawski et al. (2014) looked at the overall 
safety of vaccines during pregnancy and was not restrictive to Tdap.  After review of 
literature from 1946 to May 2013, it was concluded the benefit of antenatal vaccines 
outweighed any potential risks with the exceptions of the live influenza and live 
mumps/measles/rubella vaccines.  No safety concerns were specifically identified for the 
acellular pertussis.   
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Vaccine Effectiveness 
This literature search included two studies that looked at the effectiveness of the 
maternal Tdap vaccination in reducing the incidence of or preventing pertussis illness in 
infants.  In a case-control study conducted between October 2012 and July 2013, Dabrera 
et al. (2015) looked at rates of pertussis infection in infants of mothers who received the 
Tdap vaccine during pregnancy versus the rate of infants whose mothers were 
unvaccinated.  There were 58 cases of pertussis; only 10 of the mothers had received the 
Tdap vaccine during pregnancy whereas 39 of the 55 mothers in the control group had 
received the vaccine.  This study found a 93% vaccine effectiveness rate in mothers who 
had received the vaccine versus mothers who had not received the vaccine.  In an 
observational study of pregnant women during a pertussis outbreak in England in October 
2012, Amirthalingam et al. (2014) looked at vaccine effectiveness by comparing vaccine 
coverage in a group of women whose infants were diagnosed with pertussis versus the 
general population of pregnant women.  After widespread Tdap vaccination during 
pregnancy, England saw a 79% reduction in infant deaths from pertussis--from 2.02 per 
100,000 live births in 2012 (before the implementation of vaccination recommendation) 
to 0.43 per 100,000 live births in 2013.  With an estimated vaccine effectiveness rate of 
91%, recommendations to vaccinate all pregnant women between 27- and 36-weeks 
gestation have continued as the preferred approach in the reduction of pertussis illness.  
Immunogenicity 
The literature search yielded seven original research studies that measured 
immunogenicity, antibody levels in infants, the effect of timing on the levels and avidity 
of maternal antibodies, the humoral and cell mediated response to the Tdap vaccine in 
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pregnant and nonpregnant women, and passive immunity provided to the infant through 
breast milk after antenatal vaccination.  The primary outcome of five of the studies 
looked at the transfer of maternal antibodies to the newborn after antenatal vaccination. 
 Four of these studies were conducted at the Bnai Zion Medical Center in Faifa, 
Israel.  A prospective study by Raya, Srugo, Kessel, Peterman, Bader, Gonen et al. 
(2014) looked at the effect of the timing of maternal vaccination and how this could 
affect antibody transference through measures of maternal serum and cord serum 
antibody levels at birth.  Women were vaccinated at different stages in pregnancy--one 
group between 27 and 30 weeks, one group between 31 and 36 weeks, and the last group 
from 36 weeks to term.  Women who were vaccinated between 27 and 30 weeks had the 
highest concentrations and women vaccinated after 36 weeks had the lowest 
concentrations of maternal pertussis antibodies.  
The next study by Raya, Bamberger et al. (2015) assessed the binding strength 
between antibody and antigen and their relative avidity in relation to the timing of the 
Tdap vaccine during pregnancy.  The relative avidity of the maternal immunoglobulin G 
to the pertussis toxin was measured between 23 and 38 weeks through newborn cord 
serum.  The higher the avidity of the pertussis toxin to the immunoglobulin G, the higher 
the protective effects it would have on the infants.  This study found the highest avidity 
and, therefore, the highest level of protection to infants when their mothers were 
vaccinated between 27 and 30 weeks.  
In a prospective study, Raya, Srugo et al. (2015) wanted to assess how significant 
the decline of pertussis antibodies would be in women who were vaccinated late in 
pregnancy and whether or not there would be any lasting protection into subsequent 
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pregnancies.  The results of this study showed a significant decline in pertussis-specific 
antibodies in maternal serum at nine months and 15 months postpartum.  This study was 
significant as it enforced the importance of receiving the Tdap vaccine in every 
pregnancy regardless of previous vaccination status.   
The last study by Raya, Srugo, Kessel, Peterman, Bader, Peri et al. (2014) wanted 
to assess if there was any significant transfer of maternal pertussis-specific antibodies in 
the breastmilk of women vaccinated with Tdap late in their pregnancy.  Colostrum 
pertussis antibody levels were measured and found to be significantly higher in women 
who had received the Tdap vaccine after their 20th week.  This study not only augmented 
the data behind the support of vaccination during pregnancy but also the data supporting 
breastfeeding.   
Vilajeliu et al. (2015) conducted an observational study that sought to determine 
maternal transference of pertussis-specific antibodies from mother to unborn infant.  
Serum was measured in mothers prior to vaccination and then maternal and infant serums 
were again measured after vaccination.  It was found infants whose mothers were 
vaccinated during pregnancy had higher levels of the anti-pertussis antibodies, enough to 
protect them for at least the first two months of life.   
Munoz et al. (2014) conducted a phase 1-2, randomized, double-blind clinical trial 
whose primary outcome measured adverse events but whose secondary outcome 
measured anti-pertussis antibody levels in infants at birth, two months, and after third and 
fourth doses of DTaP.  Antibodies measured at birth and two months were significantly 
higher in infants whose mothers had received the Tdap vaccine and did not show any 
decrease in response to the DTaP vaccine received in infancy.  This study was significant 
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because it showed the Tdap vaccine in pregnancy did not alter the infant’s response to 
actively building immunity to the DTaP vaccine starting at two months.    
The last study related to immunogenicity by Huygen, Caboré, Maertens, Van 
Damme, and Leuridan (2015) measured humoral and cell-mediated immune responses in 
pregnant and non-pregnant women. Antibody response levels were measured at one 
month and one year after immunization and it was found pregnant and non-pregnant 
women had similar humoral and cell-mediated responses to the vaccine.  What was 
significant about this study was the follow up at one-year post vaccination.  Antibody 
levels had waned to the extent that there would not be sufficient transfer of maternal 
antibodies in any subsequent pregnancies, supporting the recommendation for repeat 
vaccination with every pregnancy.   
Vaccine Hesitancy 
 Regarding maternal perceptions and hesitancy of the Tdap vaccine during 
pregnancy, this literature review found four studies and one systematic review that met 
inclusion criteria.  Healy, Rench, Montesinos, Ng, and Swaim (2015) conducted a 
prospective, convenience survey of women during pregnancy at a large urban health 
center.  There were 796 surveys completed by pregnant women and 63 surveys by 
providers assessing women’s attitudes toward their provider’s recommendations, 
knowledge of recommended vaccines during pregnancy, and willingness to receive those 
vaccines.  Survey results showed pregnant women saw their provider as the most trusted 
source of information (84%) and the majority of women would be willing to receive the 
Tdap or influenza vaccine if educated on the vaccine and recommended by their provider 
(83%).   
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 In a randomized, prospective study, Payakachat, Hadden, and Ragland (2016) 
examined whether or not educational material, specifically a vaccine information sheet, 
would improve maternal vaccine uptake of the Tdap vaccine.  This study was conducted 
at two urban women’s clinics where two groups were randomized to receive the CDC 
(2015c) vaccine information sheet (VIS) and a modified VIS.  There was no statistical 
difference in the vaccine uptake between the two groups but the authors described that of 
250 women who were included in the study--whether they received the VIS or the 
modified VIS, there was a significant increase in uptake of the Tdap vaccine to 47% 
compared to the previous rate of 13%.  The authors described this study as significant as 
the higher rate of uptake could be directly attributed to increased education provided to 
the patients regarding vaccines during pregnancy.   
 Donaldson et al. (2015) conducted a cross-sectional survey of an ethnically 
diverse group of 200 women who received prenatal care through a large public health 
system in London.  The purpose of this survey was to glean a better understanding of 
what determined uptake of vaccines during pregnancy.  Of the women surveyed, only 
26% received the Tdap vaccine during pregnancy.  Regarding this poor uptake, it was 
determined only 34% of the women survey had even been offered the vaccine and only 
24% of the women reported having a discussion with their practitioner regarding the 
vaccine.  This study found the greatest barriers to vaccine uptake were lack of 
recommendation by providers and lack of accurate and timely information and education 
regarding the vaccine during pregnancy. 
 Larson et al. (2015) and the World Health Organization’s (WHO) Strategic 
Advisory Group on Experts (SAGE) on Immunization sought to define the various 
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reasons for vaccine hesitancy through the development of a survey tool.  This survey tool 
was valuable as a way of monitoring vaccine hesitancy--one of the major influences 
keeping vaccine uptake low.  These authors described the importance of their work in 
separating the vaccine refusal group from the vaccine hesitancy group and focusing 
efforts to improve uptake by targeting the vaccine hesitancy group.  This article was 
included not because it provided research data on vaccine uptake or hesitancy, but rather 
a focus for researchers and providers to aim their efforts in improving vaccination rates.  
The survey was sorted into key factors affecting vaccine uptake: contextual, vaccine 
specific, and individual or group in relation to the decision to accept, delay, or refuse 
vaccine recommendations. 
 A systematic review conducted by Wilson, Paterson, Jarret, and Larson (2015) 
systematically assessed the most up-to-date literature regarding factors that influence 
vaccine acceptance during pregnancy.  A total of 155 articles were included in the search 
looking at vaccine hesitancy regarding influenza, tetanus, and pertussis vaccines during 
pregnancy.  After review of these 155 articles, it was determined the factors affecting 
uptake of vaccines during pregnancy most cited and relevant to pregnant women included 
vaccine safety, vaccine effectiveness, no recommendation from provider, lack of 
education regarding vaccines during pregnancy, access to vaccines, cost, and conflicting 
recommendations.  The barriers most cited by providers and other health care 
professionals included inadequate training, reimbursement issues, and increased 
workload.  This systematic review on the global perspectives about vaccinations during 
pregnancy offered more concise areas to target for vaccine improvement strategies.   
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Vaccine Uptake and Improvement Strategies 
 This literature search yielded five studies that met inclusion criteria related to 
vaccine uptake and improvement strategies.  In a retrospective study of all women 
delivering at one hospital between February and June of 2013, Goldfarb et al. (2014) 
looked at the different demographics and what potential predictors influenced whether or 
not women received the Tdap vaccine during pregnancy.  The authors identified 1,467 
women, 1,194 (81.6%) of whom received the Tdap vaccine during pregnancy.  Through 
multivariable logistic regression, three factors were found to influence women in 
receiving the Tdap vaccine during pregnancy.  The first factor found women were more 
likely to receive the Tdap vaccine if they had already received the influenza vaccine 
during their current pregnancy.  The next variable showed Black women were least likely 
to receive the Tdap vaccine.  The last variable found women who delivered prematurely 
were less likely to have received the Tdap vaccine.  The purpose of this study was to 
identify disparities in women who did or did not receive the Tdap vaccination during 
pregnancy so further research could be conducted to minimize these disparities.   
 Forsyth, Plotkin, Tan, and von König (2015) reviewed all available literature 
regarding which strategies were best for protecting newborns against pertussis.  Available 
strategies that have been used in recent years in an effort to reduce infant mortality 
included Tdap in every pregnancy, immunizing all family members and anyone with 
close contact to infants less than six months old (also known as cocooning), immunizing 
both parents in immediate postpartum period, and immunizing only the mother in 
immediate postpartum period.  The authors of this article came from different countries 
around the world as experts in the Global Pertussis Initiative (GPI; Forsyth et al., 2015).  
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Through expert review of available evidence and literature, the GPI recommended Tdap 
in every pregnancy as the most effective method for reducing the burden of pertussis on 
infants.  Cocooning and immunizing either parents, or only mothers, were considered 
sufficient if Tdap was not or could not be given during pregnancy.   
 Healy, Ng, Taylor, Rench, and Swain (2015) reviewed uptake of Tdap in 
pregnancy at a large urban hospital between April 2013 and June 2014.  They reviewed 
6,577 deliveries over the course of this one+ year period.  In April 2013, the uptake of 
Tdap during pregnancy was approximately 36%.  Over the next year, provider 
recommendations increased after the release of the ACOG toolkit as well as provider 
trainings and reminders at meetings.  With the implementation of these reminders, uptake 
of Tdap increased from 36% to greater than 61% and sustained above that percentage 
starting in November, 2013.  Of note, women were categorized into different age ranges 
and race/ethnicities and like Goldfarb et al. (2014), Black women were the least likely to 
receive the Tdap immunization.  The authors reported no clear reason why this group of 
women was significantly less likely to receive the Tdap during pregnancy; further 
research will be needed to discern the exact nature of this disparity.  The overall 
conclusion of this study suggested providing education to providers and provider 
recommendations to patients are important factors in increasing the uptake of Tdap 
during pregnancy.   
 Morgan et al. (2015) evaluated how using a best-practice alert in the electronic 
health record (EHR) improved Tdap rates in pregnancy.  In a groundbreaking effort to 
reduce the burden of pertussis on infants, implementation of a best-practice alert 
increased the uptake of Tdap in pregnancy from 48% to 96.8%.  This best-practice alert 
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was programmed to appear starting at 32-weeks gestation and continue to appear with 
every visit until documented receipt of the vaccine or delivery occurred.  Use of a best-
practice alert was clearly an advantageous tool to remind providers to give Tdap during 
pregnancy but offered a logistical problem to groups of providers that could not get 
approval for changes in or did not use an EHR.    
 In a systematic review of evidence, Bechini, Tiscione, Boccalini, Levi and 
Bonanni (2012) analyzed use of the Tdap vaccine in high-risk groups such as pregnant 
women, healthcare workers, newborns, and adolescents.  Literature supported the use of 
Tdap vaccine in pregnancy as a useful tool for reducing the burden of pertussis on the 
infant population.  Studies in immunogenicity showed a correlation with higher antibody 
levels and a reduction in the risk of developing pertussis.  This review supported the 
current recommendation to provide the Tdap vaccine in every pregnancy as the primary 
strategy for protecting infants from pertussis. 
 A cluster-randomized trial by Chamberlain et al. (2015) examined the results of a 
multi-component antenatal vaccine package targeted at improving Tdap and influenza 
uptake during pregnancy.  Chamberlain et al. offered different strategies for increasing 
vaccine rates during pregnancy including posters, brochures, lapel buttons, a vaccine 
champion, education materials at the practice and patient levels, and provider education 
at the provider level.  This study did not find a statistically significant increase in the 
uptake of vaccines during pregnancy but the authors believed that because it was 
introduced late in the flu season, the results were confounded.  One statistically 
significant finding from this study was the correlation between provider recommendation 
and vaccine uptake.  Patients reported the single most convincing reason they would 
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accept the Tdap or influenza vaccine was if the recommendation came from their 
provider.   
Summary 
 This literature review offered a summary of evidence regarding vaccine safety, 
vaccine effectiveness, immunogenicity, vaccine hesitancy, and different strategies that 
had been used to increase vaccine uptake during pregnancy.  Studies looking at the safety 
of the Tdap vaccine found no significant adverse events related to infant growth and 
development, major congenital malformations, or any complications of pregnancy such 
as preterm birth, spontaneous abortions, small or large for gestational age babies, or 
stillbirths.  Two major studies regarding vaccine effectiveness found the Tdap vaccine 
given during pregnancy had a greater than 93% effectiveness rate at preventing pertussis 
in infants less than two months old.  Immunogenicity studies measured amounts of 
antibodies passed from mother to infant through serum, colostrum, and breast milk, and 
found infants received the highest number of antibodies if the vaccine was given between 
27- and 36-weeks of pregnancy.   
The studies examining vaccine hesitancy and uptake improvement methods were 
important in the development of this capstone project.  Multiple studies showed providers 
were the most trusted source of information regarding vaccine safety and effectiveness; 
provider recommendation yielded the most success in improving the rates of Tdap 
immunization during pregnancy.  There was no gap in evidence supporting the safety, 
efficacy, or immunogenicity of the Tdap vaccine during pregnancy but was a gap in the 
translation of this evidence to the care of pregnant women and their families.  Therefore, 
increasing provider adherence to national recommendations through targeted strategies 
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was likely to yield the best outcomes and have the highest likelihood of success in 
increasing rates of Tdap immunization during pregnancy. 
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CHAPTER III 
 
 
METHODS AND EVALUATION 
 
 
Providing the Tdap immunization to mothers while pregnant reduces newborn and 
infant complications from pertussis illnesses; yet, there remains a disparity between the 
evidence and immunization rates.  The exact nature of this disparity is not fully 
understood but studies revealed provider recommendation remained the single most 
effective way of increasing Tdap immunization rates in pregnancy.  This project was a 
quality improvement (QI) process that focused on updating and improving current 
practice in an effort to increase the rate of women who would receive the Tdap vaccine 
during pregnancy with the end result of preventing pertussis illness in newborns and 
infants less than two months old.  There were three primary objectives of this QI project: 
(a) update and improve the current provider reminder tool, (b) increase provider 
awareness of national recommendations, and (c) increase medical assistant (MA) 
awareness and compliance with the current adult standing order for Td/Tdap vaccine in 
adults.  Each objective had an associated intervention, evaluation plan, and measurable 
outcomes.  The next section describes the setting, methods in detail, and evaluation plan.   
Setting 
 North Colorado Family Medicine (NCFM) is a large family medicine clinic and 
physician residency program located in the center of Greeley, Colorado.  This family 
medicine clinic sees patients of every age, gender, ethnicity, and socioeconomic status.  
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As one of few family medicine clinics in Greeley that accepts Medicaid, these patients 
comprise a large portion of the patient population.  On a typical day, this clinic will have 
19-20 patients per provider and 10-12 providers per day.  The clinic consists of 
attending/faculty physicians, residents of medical and osteopathic medicine, podiatry 
residents, nurse practitioners, medical assistants, and ancillary administrative staff.  North 
Colorado Family Medicine is part of a larger hospital system in northern Colorado but 
functions independently of the system with regard to day-to-day operations.   
 The first step in implementing the process improvement plan was to understand 
what daily practice was and where there might be an opportunity for improvement.  
North Colorado Family Medicine has a specific process in caring for pregnant patients 
from planning and conception through birth.  When women find out they are pregnant 
and inform their providers or clinic staff, the first step is to schedule an obstetrics (OB) 
intake visit that focuses mainly on history including the woman’s medical and surgical 
history as well as pregnancy history and risk factors.  Prior to the OB intake visit, the 
clinic staff puts together a physical chart that includes questions related to history, past 
pregnancies, a checklist regarding pregnancy education that is broken down by trimester, 
and a checklist regarding specific interventions meant to guide the provider in avoiding 
missing important diagnostic tests and interventions throughout the pregnancy.   
This visit is an opportunity for the provider to answer questions and provide an 
overview of pregnancy education items and the timeline for specific interventions.  Lab 
work is ordered at the OB intake visit; patients are escorted to the lab after their visit or 
have the opportunity to come back prior to the next visit to have their blood drawn.  After 
the OB intake visit is completed, an OB physical is scheduled.  This visit includes a 
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complete physical exam, pelvic exam, pap smear if indicated, and review of lab work.  
Once these initial visits are completed, the remainder of the visits are considered OB 
maintenance visits where interventions such as immunizations and additional tests are 
completed as part of those routine visits.  The physical OB chart is pulled for every visit 
including the routine maintenance visits as a resource for the provider so that it can be 
referenced for timing and recommendations for testing and interventions.   
Three interventions in this quality improvement project targeted the three primary 
objectives.  These interventions included an updated provider reminder tool that was 
laminated and placed in the physical OB chart, an educational fact sheet on the Tdap in 
pregnancy, and an educational meeting with medical assistants.  Each intervention and 
evaluation method are discussed in more detail in the next section. 
Intervention Plan 
Objective One: Provider  
Reminder Tool 
Considering current practice at North Colorado Family Medicine, the focus of this 
intervention was to build on and improve current practice by utilizing a provider 
reminder method already in use.  Prior to the intervention, a provider reminder checklist 
was in use per the description of current practice.  This checklist was divided by 
trimesters and included when to order specific diagnostic and lab tests as well as when to 
initiate interventions.  It was noted that this reminder checklist did not include 
administration of vaccines during pregnancy as recommended by ACOG and the 
Advisory Committee on Immunization Practices for the CDC (2016).   
This checklist was widely used by providers and did not require any education as 
to its existence.  This checklist was printed on pink paper so it would stand out to 
37 
 
providers, was laminated, and reusable in order to reduce waste.  A picture of the 
checklist used in previous practice can be found in Appendix A followed by the updated 
checklist that replaced the previous list at the start of the project (see Appendix B).  The 
purpose of improving the previous checklist was to use a system already in place by 
adding a visual reminder to providers to ensure the Tdap was given in every pregnancy.  
Due to timing of this intervention, improving uptake of the influenza vaccine during 
pregnancy was not formally included in this process improvement.  However, at the 
request of the medical director and nursing supervisor, a reminder to administer the 
influenza vaccine was also added to the checklist.  This was not part of this capstone and 
was not evaluated but was added to the updated reminder checklist at the clinic’s request.  
In an effort to improve the likelihood of providers recognizing the updated checklist, the 
new list was printed on purple paper, laminated in the clinic, and given to administrators 
in the medical records office who were responsible for putting together the physical 
charts. 
This clinic serves as a residency clinic in northern Colorado so it was expected 
there would be gaps in knowledge between first year residents, second year residents, 
third year residents, attending physicians, and nurse practitioners.  The provider reminder 
tool exists to bridge the knowledge gaps for newer providers and has been in existence at 
the clinic for several years.  Current practice has attending physicians, residents in their 
second and third years, and nurse practitioners orienting newer residents to the use of the 
physical chart used for OB patients so there was no need for this author to provide any 
additional education regarding the use of the reminder tool.   
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Objective Two: Educational Material  
in Patient Information Packet 
Prior to this intervention, the process was to provide every new obstetric patient 
with an informational packet that included general pregnancy education, diet tips, local 
classes, and available resources for all pregnant women.  Information in these packets 
was pre-approved by the nursing and medical directors for the clinic, put together by 
existing ancillary administrative staff, and then distributed to patients at the time of their 
intake appointment.  Packets were given to the patients at check-in by the front desk staff 
with the expectation that the provider doing the intake appointment would go over the 
educational material with every individual patient.  Prior to this intervention, these 
packets did not contain any information regarding the safety and efficacy of vaccines 
during pregnancy.  Whether or not this education was routinely provided by each 
provider was not formally evaluated.   
To meet the second objective--increasing provider awareness and compliance 
with the national recommendations of providing every pregnant patient with a Tdap 
vaccine between 27- and 36-weeks gestation, a CDC (2015c) patient information sheet 
(see Appendix C) was placed in all of the patient education packets.  This information 
sheet was available on the CDC website at no charge, printed at the clinic, and placed in 
the packets by ancillary staff.  Although this sheet was written with pregnant women as 
the primary target audience, the objective of this intervention was to offer a reminder to 
every provider of the existing recommendation to offer the Tdap in every pregnancy.  
This intervention not only provided a visual reminder to start the conversation with the 
patient regarding the Tdap during pregnancy at the initial OB intake visit but had an 
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added benefit of augmenting patient education regarding the safety and efficacy of the 
Tdap vaccine during pregnancy. 
Objective Three: Medical Assistant  
Education 
The next tier of this intervention plan was to include two educational sessions 
with the clinic’s medical assistants (MA).  It was in the scope of every MA at North 
Colorado Family Medicine (NCFM) to initiate the order for and administer all childhood 
and adult vaccinations.  The MAs at NCFM have two existing standing orders for adults 
and children over seven-years-old, specifically for the Td/DTaP/Tdap vaccines.  These 
standing orders delineate that Tdap is to be given to pregnant women between 27 and 36 
weeks (see Appendix D), and are based on the CDC Adult Vaccine Schedule (see 
Appendix E).  In observing the MA workflow, it was noted that Tdap vaccines during 
pregnancy were rarely initiated by the MA; administration relied on the provider placing 
the order and giving the MA a verbal order to administer the vaccine.  At the start of this 
project, it was assumed the percentage of MAs aware of this standing order was low.   
Medical assistant education was provided at two separate mandatory staff 
meetings.  The MAs were presented with a short PowerPoint presentation that included a 
picture of the standing order, the gestational ages at which the Tdap should be 
administered during pregnancy, and background information on pertussis and why the 
vaccine is so important to mothers and their unborn children (see Appendix F).  The MAs 
were instructed to defer all refusals to providers so education could be augmented by 
physicians and nurse practitioners in an effort to improve Tdap vaccine rates.   
The first educational sessions were offered at the first two mandatory meetings in 
June and July.  The initial meeting was targeted at the majority of the staff but accounting 
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for possible sick days and staff turnover, the second educational session offered the same 
PowerPoint and education to any new staff or staff who had missed the first meeting.  
Attendance at the meetings was approved by the office manager as well as the nursing 
director per the Statement of Mutual Agreement (see Appendix G). 
No changes were made to the current standing order for the clinic as it covered all 
adult and adolescent patients, including those who were pregnant, to receive the Tdap 
vaccine.  The purpose of the education provided to the MAs was to serve as a reminder of 
a standing order for Tdap and pregnancy, provide education as to the timing of the 
vaccine, and provide information regarding why the vaccine is important related to 
decreased incidence of pertussis in the newborn and infant population.  Increasing patient 
education was an important piece of this intervention bundle; however, it was not 
considered an objective as it was not feasible to evaluate the outcomes of this education 
in the current patient population within the project timeframe.   
Timeline 
 May 20, 2016--Capstone proposal defense 
 May 26, 2016--Submit to University of Northern Colorado Institutional 
Review Board (IRB; see Appendix H) 
 June 13, 2016--Initiation of capstone quality improvement project following 
IRB approval 
o Checklist updated and given to administration for printing and 
laminating 
o PowerPoint completed for medical assistant education 
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o Patient educational material distributed to administrators for inclusion 
into new patient OB packs by nursing director 
 June 13, 2016--Initiate chart review to determine current uptake of Tdap 
during pregnancy in clinic from 2012 to present  
 June 14, 2016--First meeting with medical assistants and nursing director  
 July 5, 2016--Second meeting with medical assistants and nursing director 
 September 23, 2016--Completion of capstone quality improvement project 
 September 26, 2016--Distribution of evaluations to providers, residents, and 
medical assistants 
 September 26, 2016--Initiate chart review for compliance of Tdap vaccine 
uptake between June 13 and September 23, 2016 
 October 18, 2016--Capstone defense   
Resources 
 This project did not require many resources for implementation, evaluation, and 
maintenance.  The three interventions included in this project were meant to build upon 
and improve existing practice flow.  This clinic consists of family medicine residents, 
attending physicians, nurse practitioners, medical assistants, 28 patient exam rooms, four 
minor treatment rooms, one major procedure room, in-house laboratory, nutritional 
counselor, and in-house behavioral specialists. Ancillary administrative staff include 
individuals who work at the front desk to check patients in, hand out and collect patient 
information, update patient charts, and answer questions.  There are individuals who 
work to set up referrals, code charts, medical records, billing, residency services, and 
office management.  Office supplies are plentiful and included in the pre-existing budget.  
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The clinic has printers, scanners, copy machines, laminating machines, and computers in-
house that are provided for all staff and residents.   
The cost to implement and maintain this intervention plan was minimal and was 
absorbed into the pre-existing clinic budget.  The educational materials were available at 
no cost on the CDC (2015c) website.  The link for this material was emailed to the 
nursing director at her request and then the task of printing and placing in the new OB 
packets was assigned to one of the administrative front desk staff.  There was no need to 
hire additional personnel as the task of making the packets had already been assigned so 
the addition of the educational material was not an extra burden on the clinic.   
Feasibility and Sustainability 
This project was based on improving three activities already in place at North 
Colorado Family Medicine (NCFM).  Providing patients with educational material at the 
OB intake visit was standard practice so the addition of the Tdap patient education 
material served as supplemental material to reinforce the safety and efficacy of the 
vaccine for pregnant patients and family members who might be hesitant or might not 
even know of the recommendation to immunize every pregnant patient.  This educational 
material was available to all providers through the CDC (2015c) website free of charge.  
Minimal additional costs included the paper, ink, and wear on the printer but these costs 
were insignificant and did not require that additional materials be purchased.  The time 
spent on creating the new OB educational packets was standard at the clinic so the extra 
time spent adding the Tdap educational sheet was negligible regarding the increased cost 
to pay staff and decreased productivity.  There was no intention to change practice 
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regarding the use of the new pregnant patient educational material so this project should 
be easy to maintain.   
The education to the MAs was provided at a regularly scheduled monthly staff 
meeting so no additional costs were required to pay staff to attend.  The PowerPoint and 
educational materials were completed by this author at no cost to the facility.  This 
intervention is sustainable as the use of standing orders is regular practice for the MAs in 
this clinic setting.   
In October 2014, the Public Health Service office through the CDC sent out a 
letter to providers imploring their cooperation with their efforts in improving vaccine 
rates during pregnancy (NFID, 2014).  This letter (see Appendix I) reiterates to providers 
how important it is to ensure the Tdap vaccine is provided in every pregnancy and 
reminds providers that research confirms the provider recommendation for vaccines 
during pregnancy as being essential in uptake (NFID, 2014).  The CDC outlined steps for 
increasing vaccination rates during pregnancy with the following four steps: (a) always 
review the immunization status of every patient at every visit, (b) recommend any 
vaccines due at the time of the visit if indicated by the adult vaccination schedule, (c) 
administer the vaccine or refer to a provider who is able to administer the vaccine, and 
(d) document all vaccines given in electronic health record as well as state registry if 
possible.  This call to action by the CDC reminds all providers of their duty to provide 
vaccines during pregnancy in an effort to reduce mortality in infants from vaccine 
preventable illnesses (NFID, 2014). 
As per the Statement of Mutual Agreement (see Appendix G) and agreed upon by 
the nursing director and medical director, the providers of North Colorado Family 
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Medicine are invested in working toward ensuring Tdap in every pregnancy.  It has been 
demonstrated that pertussis prevention in infants is a priority of national organizations 
such as the CDC, ACIP, American Academy of Family Physicians, American College of 
Nurse-Midwives, American Academy of Pediatrics, and ACOG (NFID, 2014).  The 
providers are invested in providing the best care to every patient as outlined by the 
Banner Health (2016a) mission and vision, ensuring the sustainability of this 
intervention. 
Evaluation Plan 
After IRB approval was obtained (see Appendix H), initiation of this project 
started with a retrospective chart review of every patient who received her prenatal care 
through North Colorado Family Medicine between October 2012 and December 2015.  
The only feasible way of obtaining the data needed for evaluation of this project was 
through individual chart review.  The office manager pulled all of the delivery codes for 
the specified time frame and provided the names and birthdays of those patients for chart 
review.  The chart review provided a baseline percentage of patients who received the 
Tdap during pregnancy after release of the national recommendations (CDC, 2013b).  It 
was anticipated that compliance would have increased since the national 
recommendations for Tdap in every pregnancy were published so an average of the years 
2013, 2014, and 2015 were calculated and reported as the baseline percentage of 
compliance.  Patient confidentiality was maintained throughout the process by only 
conducting reviews in the clinic setting through a secure database after obtaining written 
permission from the office manager.  No identifying markers were used in this process, 
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no patient identifiers were recorded, and the identity of all patient health information was 
kept confidential by clinic and organizational standards.  
Establishing a Baseline: National  
Rates 
National rates of Tdap uptake during pregnancy have fluctuated based on 
different factors including year, location, socioeconomic status, and ethnicity.  National 
studies have found uptake of Tdap during pregnancy between 14.3%-55.7%, depending 
on the size and location of the populations measured (Ahluwalia et al., 2015; Harriman & 
Winter, 2014; Housey et al., 2014).  These studies also found the lower percentages of 
Tdap vaccine uptake were associated with the amount and quality of prenatal care 
received.   
Establishing a Baseline: County and  
State Rates in Colorado 
No data were available on the rates of Tdap vaccination during pregnancy in 
Colorado; thus, there was no way to determine if the percentage determined by chart 
review of patients receiving prenatal care at North Colorado Family Medicine was 
representative of county or state rates.  There was speculation that women who received 
the vaccine from a family practice clinic had higher uptake rates versus those who 
received their prenatal care at an OB/GYN due to the availability of vaccines in the 
primary care setting (Cherry, 2015).  This speculation was based on the fact that the 
United Kingdom has had higher vaccine uptake rates since their recommendation to start 
vaccinating all women with Tdap in 2013 and the majority of women in the United 
Kingdom received their prenatal care through family practice clinics versus OB/GYNs 
(Cherry, 2015).   
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The retrospective chart review established a baseline from which the overall 
vaccine improvement rates could be measured.  The percentage measured for evaluation 
of the intervention was not an accurate representation of the overall increase in vaccine 
rates because of the short project timeframe relative to the overall length of pregnancies.  
The intervention timeframe was 10 weeks; since it was unknown how many pregnant 
patients would be appropriate for the Tdap vaccine during this timeframe, an additional 
evaluation method was used to measure the outcomes of the three objectives.  Each 
objective was measured by a separate post-intervention survey.  Each survey included 
two questions that were measured by a 5-point Likert scale with the following answer 
options:  Strongly Agree, Agree, Neutral, Disagree, and Strongly Disagree.  The two 
provider surveys were combined into one to minimize the use of clinic resources.  
Examples of each survey can be found in Appendix J. 
Evaluation Method for Objective  
One 
The first objective was to update and improve current practice to increase the rate 
of Tdap immunizations in pregnant women at North Colorado Family Medicine.  This 
objective was met by updating and improving an existing provider reminder system that 
was well established in current practice.  The expected outcome of this intervention was 
to improve Tdap vaccination rates in pregnant patients by reminding providers to offer 
the vaccine.  It was evaluated in two ways: (a) pre- and post-intervention chart reviews of 
Tdap vaccine rates in pregnant women seen at North Colorado Family Medicine and (b) 
post-intervention provider survey assessing use of implemented reminder tool (see 
Appendix J). 
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Once the pre-intervention baseline percentage of Tdap immunization rates during 
pregnancy was established, then evaluation of the intervention was done through post-
intervention chart review.  This method was described in detail earlier in this section and 
the expected outcome of this intervention was an increase in the rate of Tdap 
immunizations during pregnancy.  A secondary method of evaluation was used to assess 
the usefulness of the updated provider reminder tool by using a post-intervention provider 
survey.  This survey was measured on a 5-point Likert scale (see Appendix J) and 
included two statements:  
1. This tool will be useful in reminding you to facilitate the administration of 
the Tdap vaccine in every pregnant patient at 27-36 weeks.   
2. This updated tool will be beneficial in current practice. 
Evaluation Method of Objective  
Two 
The second objective was to increase provider awareness and compliance with the 
national recommendations of providing every pregnant patient with a Tdap vaccine 
between 27 and 36 weeks gestation.  This objective was met by placing a patient 
education sheet in the patient education packet distributed to every patient and discussed 
in detail by providers at initial appointment.  There were two expected outcomes for this 
intervention: (a) initiate a reminder to providers to discuss safety and efficacy of the Tdap 
vaccine and to make an initial recommendation to have the vaccine given during an office 
visit between 27 and 36 weeks, and (b) increase uptake of the Tdap vaccine during 
pregnancy.  The post-intervention chart review was the primary method of evaluation for 
each objective and the secondary method of evaluation for each individual objective was 
the post-intervention survey.  For this objective, the providers were given a survey 
48 
 
measured on a 5-point Likert scale (see Appendix J) that included the following 
statements: 
1. The Tdap in pregnancy educational material reminded you to discuss the 
vaccine with your patients during the OB intake. 
2. This educational material will be beneficial in current practice. 
Evaluation Method for Objective  
Three 
The third objective was to increase medical assistant awareness and compliance 
with the current standing order of administering the Tdap vaccine to all pregnant patients.  
This objective was met by providing education to the medical assistants regarding the 
existence of an adult vaccine standing order.  This standing order was already in use at 
the clinic prior to the intervention.  The intervention focused on educating all MAs to its 
existence with additional education regarding when the vaccine should be given and what 
steps to take if the patient should refuse.  The expected outcome of this intervention was 
an increase in the rates of Tdap vaccines given and was evaluated by comparison of pre- 
and post-intervention chart review and post-intervention survey evaluating the 
educational sessions and how they improved the use of the current clinic standing order.  
Evaluation of this last objective--increasing MA compliance with the existing standing 
order--was measured by a Likert scale similar to the provider survey (see Appendix J) 
that included the following questions.   
1. Prior to the educational session, were you aware that it is within the scope of 
your practice to initiate the Tdap vaccine in all pregnant women between 27 
and 36 weeks? 
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2. After the educational session provided, will you now administer the Tdap 
vaccine to every pregnant woman between 27 and 36 weeks? 
3. If a patient refuses the Tdap vaccine, will you refer this refusal to the 
patient’s provider to provide additional education about the vaccine? 
Each intervention was targeted at a specific point in the care of the pregnant 
patient where there would be the greatest chance for omission of the national 
recommendation to administer the Tdap vaccine to every pregnant patient between 27 
and 36 weeks.  To this end, each objective was evaluated with a comparison of post-
intervention vaccine rates with pre-intervention vaccine rates.  The post-intervention rates 
were measured at the end of the 10-week intervention period and are reported in the 
following chapter.  Each individual objective was then measured by provider and MA 
surveys and reported as a percentage of providers and MAs who indicated agreement 
with the intervention as (a) beneficial to practice, (b) neutral, and (c) did not find the 
intervention beneficial. 
Institutional Review Board 
This quality improvement (QI) project was approved by the IRB at the University 
of Northern Colorado (see Appendix H).  As this QI project did not involve collecting 
data from human subjects, only medical records including pre- and post-intervention 
chart review of existing pregnant patients, it was granted expedited status.  Education 
provided to the pregnant patients during the OB uptake and to the medical assistants 
during monthly meetings was already standard practice in the clinical setting so no 
addition resources were needed.  North Colorado Family Medicine is a medical residency 
program where each doctor is required to do a similar capstone project to complete his or 
50 
 
her residency.  Due to the large volume of capstone projects completed through NCFM 
every year, the medical director, representing the Banner system, had implemented a 
review system that gave the medical director of the clinic authority to determine if a 
project was exempt from IRB review through Banner Health.  Per the medical director of 
NCFM, this capstone met requirements to be exempt from review through the Banner 
Health IRB.  Any information obtained through the clinic for use within this project 
remains confidential to protect the patients as well as the integrity of the clinic.  Further, 
any data reported about the project were group or aggregate data and did not involve 
patient or staff identifying information.  
Summary 
 Pertussis is highly contagious but preventable due to the widespread use of 
vaccines.  The national recommendation (CDC, 2013b) to immunize every pregnant 
woman as a method for protecting unborn infants was released in 2012 yet nationwide 
uptake has remained low.  This QI project was aimed at improving and updating existing 
practices at North Colorado Family Medicine to align with the national recommendation.  
National and international research offered evidence to support the use of the Tdap 
vaccine during pregnancy as a method of reducing the burden of the pertussis illness on 
newborns and infants.  The benefits of this QI project included providing passive 
immunity to newborns and infants for pertussis, offering additional protection to mothers, 
and increasing provider awareness of the importance of providing the Tdap in every 
pregnancy.   
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CHAPTER IV 
 
 
RESULTS AND OUTCOMES 
 
 
 The purpose of this project was to improve the rates of Tdap in the pregnant 
population at North Colorado Family Medicine (NCFM) in Greeley, Colorado.  The 
recommendation to providers to give a Tdap in every pregnancy was published in 
October 2012 by the Centers for Disease Control (2013b) in conjunction with the 
American Council for Immunization Practices.  This project was targeted at improving 
the rates of Tdap vaccines given to pregnant women by offering education and reminders 
to clinic providers and medical assistants (MA) as the available literature suggested 
provider recommendation offered the highest success rates for improving Tdap rates in 
other settings.    
Three specific and measurable objectives were implemented:  
1. Update and improve current practice to increase the rate of Tdap 
immunizations in pregnant women at North Colorado Family Medicine. 
2. Increase provider awareness and compliance with the national 
recommendations of providing every pregnant patient with a Tdap vaccine 
between 27 and 36 weeks gestation. 
3. Increase medical assistant awareness and compliance with current standing 
order to administer all pregnant patients with Tdap vaccine. 
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The first step in the evaluation process was to determine the population of 
pregnant women seen in the clinic to predict sustainability and generalizability in the 
general population.  In 2015, there were 18,650 patient visits at NCFM with 2,035 of 
those visits coded for pregnancy.  This number was only an approximation but aligned 
with the pre-intervention estimate that the pregnant population accounted for roughly 
11% of the patient population in northern Colorado.   
It was anticipated the rate of compliance with the national recommendations 
would fluctuate after the new recommendation was implemented in October 2012.  
Therefore, to determine a pre-intervention baseline, the average rates for 2013, 2014, and 
2015 were examined.  Pre-intervention vaccine rates were computed by individual chart 
review after delivery codes were provided by the clinic office manager.  In 2013, there 
were 112 deliveries; 65 of those women were given the Tdap vaccine and 47 women did 
not receive the vaccine for a compliance rate of 58%.  In 2014, there were 145 total 
deliveries; 99 of those women were given the Tdap vaccine and 46 women did not 
receive the vaccine for a compliance rate of 68%.  In 2015, there were 137 deliveries; 110 
of those women were given the Tdap vaccine and 27 did not receive the vaccine for a 
compliance rate of 80%.  As predicted, there was a steady increase in compliance from 
the publication of the national recommendation (CDC, 2013b).  The average of those 
three years (69%) was used as the pre-intervention baseline as this was estimated to more 
likely represent the general population.   
It is important to note the delivery codes were only provided for Banner 
associated hospitals; thus, women who received care at NCFM but delivered outside of 
the system were excluded.  Another confounding variable included women who might 
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have been given the vaccine at another location or might have received prenatal care from 
an unassociated provider.   
Outcomes of Objectives 
Objective One 
The first objective was to update and improve current practice to increase the rate 
of Tdap immunizations in pregnant women at North Colorado Family Medicine.  This 
objective was accomplished by updating a pre-existing provider checklist to include a 
reminder to give the Tdap vaccine between 27 and 36 weeks.  This objective was 
measured by evaluation and comparison of pre- and post-intervention vaccine rates in 
pregnant women.  The established baseline pre-intervention compliance rate was 69%.  
Post-intervention chart review included 74 patients who received prenatal care in the 
intervention time frame.  Of the 74 pregnant patients seen in the intervention timeframe, 
65 received the Tdap vaccine for a compliance rate of 88%.  
The second method of evaluation to measure the outcomes of objective one was 
with a post-intervention provider survey to assess whether or not the providers found this 
updated checklist beneficial by asking the following two questions: 
1. Will this tool be useful in reminding you to facilitate the administration of 
the Tdap vaccine in every pregnant patient at 27-36 weeks?   
2. Will this updated tool be beneficial in current practice? 
This survey was measured on a 5-point Likert scale from 1 = Strongly disagree to 5 = 
Strongly agree.  Of the 35 surveys distributed to the faculty physicians, nurse 
practitioners, and medical residents, 17 surveys were returned for a return rate of 49%.  
All of the providers who returned the survey agreed or strongly agreed this updated 
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checklist was a useful tool for reminding him or her to administer the Tdap vaccine at 27-
36 weeks of pregnancy. 
 Key facilitators.  No education was required on the implementation or use of the 
updated checklist because its use was already well-established in current practice.  The 
medical residents found this tool especially helpful in developing their practice with OB 
patients as the checklist of tasks in the three trimesters can be overwhelming to 
unexperienced providers.  The faculty physicians and nurse practitioners informally 
reported they appreciated the update as the new checklist and new paper color offered a 
visual reminder to existence of the tool.   
 Key barriers.  A few barriers were associated with this intervention including a 
minor delay in the rollout process, the start of a new cohort of medical residents, and the 
rollout of the new electronic health record.  The new residents started the first week of 
July, which was assumed to create a transient decrease in vaccine compliance that likely 
improved after the first two to three weeks.  There was a delay in the rollout of the 
checklist as the nursing director took this opportunity to update other parts of it.   
The last barrier was the implementation of the new electronic health record, 
Cerner, which occurred three weeks into the intervention window.  This was estimated to 
be the most significant barrier and might have resulted in either inaccurate or reduced 
post-intervention vaccine rates.  The office manager pulled ICD-10 codes for pregnancy 
related visits as well as the codes for administration of the Tdap vaccine.  Possible 
barriers related to this process included pregnant patients who received the vaccine where 
there was missed documentation, women who were not given the vaccine at the 
appropriate time related to the stress caused to the providers and MAs during the rollout 
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process, or charts that were missed due to this author’s relative unfamiliarity with the 
new electronic health record compared to the previous system.  The significance of these 
barriers on vaccine rates was unknown but there was likely only a minor decrease in rates 
due to the relatively long intervention window.   
Objective Two 
The second objective focused on increasing provider awareness and compliance 
with the national recommendation (CDC, 2013b) of providing every pregnant patient 
with a Tdap vaccine between 27 and 36 weeks gestation.  This objective was met by 
placing a CDC (2015c) authored patient education sheet in the patient education packet 
that was distributed to every patient.  Standard practice in the clinic is the provider 
discusses the content of the packet with each pregnant patient at the initial OB intake 
visit.  There were two expected outcomes for this intervention: (a) Providers would be 
reminded to discuss safety and efficacy and make initial recommendations to be 
vaccinated during an office visit between 27 and 36 weeks, and (b) administration rates 
of the vaccine during pregnancy would increase.  These objectives were measured by 
evaluation and comparison of pre- and post-intervention vaccine rates in pregnant 
women.  The established baseline pre-intervention compliance rate was 69%.  Post-
intervention chart review looked at 74 patients who received prenatal care in the 
intervention time frame; 65 of 74 pregnant women received the vaccine for a compliance 
rate of 88%.   
The second method of evaluation to measure the outcomes of objective two was 
with a post-intervention provider survey to assess whether or not the providers found this 
updated checklist beneficial by asking the following two questions: 
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1. Did the Tdap in pregnancy educational material remind you to discuss the 
vaccine with your patients during the OB intake? 
2. Will this educational material be beneficial in current practice? 
This survey was measured on a 5-point Likert scale from Strongly disagree to Strongly 
agree.  Of the 35 surveys distributed to the faculty physicians, nurse practitioners, and 
medical residents, 17 surveys were returned for a return rate of 49%.  Of the 17 providers 
who returned a survey, 15 agreed or strongly agreed the Tdap in pregnancy educational 
material reminded them to discuss the vaccine with their patients at the initial intake 
appointment and felt that this tool would be useful to their practice.  One provider noted 
he/she was not aware of the material and one provider left feedback that the timing of the 
educational material was too early in the pregnancy to be useful.   
Key facilitators.  As with the first objective, this intervention focused on 
updating and improving on existing practice.  The use of the educational packet was 
established practice and did not require any education for physicians and nurse 
practitioners.  The information sheet was free from the CDC (2015c) and did not require 
any additional resources or special permission for use.  This educational material targeted 
the pregnant patient population and while acting as a reminder to the providers and had 
the added benefit of providing additional education to patients and families.  The 
outcome of patient education was not in the scope of this capstone project and the benefit 
is only predicted informally.   
Key barriers.  The barriers for achievement of this objective were much the same 
as with the first objective with regard to the start of a new cohort of medical residents as 
well as the switch to the new electronic health record.  These barriers were expected to 
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only minimally affect the outcomes of the chart review for compliance rates.  There was a 
slight cost in printing the new CDC educational material as the clinic did opt to print 
these materials in colored ink for the benefit of the patients. 
Objective Three 
The third objective was implemented in an effort to increase medical assistant 
awareness and compliance with the current standing order to administer the Tdap vaccine 
to all pregnant patients.  This objective was met by providing education to the medical 
assistants regarding the existence of an adult vaccine standing order based on the most 
current adult vaccine schedule.  This vaccine schedule recommended administering the 
Tdap to all pregnant patients between 27 and 36 weeks.  The intervention focused on 
educating all MAs to its existence with additional education regarding when the vaccine 
should be given and what steps to take if the patient should refuse.  The expected 
outcome of this intervention was an increase in the rates of Tdap vaccines given and was 
evaluated by comparison of pre- and post-intervention chart review and post-intervention 
survey evaluating the educational sessions and how they improved the use of the current 
clinic standing order.  The established baseline pre-intervention compliance rate was 
69%.  Post-intervention chart review looked at 74 patients who received prenatal care in 
the intervention time frame.  Of the 74 patients reviewed, 65 women received the Tdap 
vaccine for a compliance rate of 88%.   
The second method of evaluation to measure the outcome of objective three was 
with a post-intervention provider survey to assess whether or not the providers found this 
updated checklist beneficial by asking the following two questions: 
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1. Prior to the educational session, were you aware that it is within the scope of 
your practice to initiate the Tdap vaccine in all pregnant women between 27 
and 36 weeks? 
2. After the educational session provided, will you initiate Tdap vaccine to 
every pregnant woman between 27 and 36 weeks? 
3. If a patient refuses the Tdap vaccine, will you defer this refusal to the 
patient’s provider to provide additional education about the vaccine? 
This survey was measured on a 5-point Likert scale from Strongly disagree to Strongly 
agree.  Of the 12 surveys distributed to the medical assistants, nine surveys were returned 
for a return rate of 75%.  Nine of the nine MAs agreed or strongly agreed the educational 
sessions helped them feel more empowered to initiate the Tdap vaccine to pregnant 
patients between 27 and 36 weeks gestation.  Of the nine surveys returned by the medical 
assistants, seven were not aware of the standing order to give this vaccine prior to the 
educational session but post-intervention survey results showed all MAs would initiate 
the Tdap vaccine during pregnancy.  All of the medical assistants who returned surveys 
agreed or strongly agreed to defer all refusals to the patient’s provider for further 
education.  This researcher felt this last piece of the intervention was especially important 
as vaccine refusals had not always been reported to the providers; the literature indicated 
provider education and recommendation had the highest rate of success for improving 
vaccine administration rates. 
Key facilitators.  This objective was relatively easy to accomplish as the 
education provided to the medical assistants was done at mandatory monthly meetings 
and did not require any additional time at the clinic.  The medical assistants were paid for 
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this educational session as it was mandatory.  The PowerPoint was made by this 
researcher prior to the educational meeting, did not utilize any clinic resources, nor was it 
associated with any added cost.  The presentation was built into the meetings by the 
nursing director and did not detract from any additional clinic education. 
Key barriers.  The barriers for achieving this objective were much the same as 
the first two objectives with regard to the switch to the new electronic health record.  The 
new workflow process with the new electronic health record required the providers to 
order all vaccines given whereas previous workflow allowed for the MAs to order 
vaccines given.  It was assumed to be a barrier in the overall outcome of vaccine rates as 
there were likely fallouts in the ordering and documentation of the vaccine 
administration.  Another barrier likely affecting the overall outcomes of this objective 
was the high turnover rate of MAs in the office.   
Unintended Consequences 
 This capstone project had the overall intention of improving the Tdap rates in 
pregnancy to offer passive immunity and indirectly decrease the morbidity and mortality 
rates associated with pertussis in newborns and infants.  It was out of the scope of this 
capstone to measure any associated decrease in pertussis rates in this age group but any 
indirect decrease in pertussis rates was considered a positive consequence of this project.   
 Due to the seasonal timing of this intervention, it was not possible to include a 
strategy to improve influenza vaccine rates in pregnant women.  At the request of the 
nursing director, a reminder to give the influenza vaccine at any stage in pregnancy 
during flu season was added to the provider checklist (see Appendix B).  There was no 
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way of estimating the unintended consequences of this intervention but it was assumed 
this would only be a benefit to the providers and patients.   
Summary 
 The results of this intervention showed an increase in the rates of Tdap given to 
the pregnant population seen at North Colorado Family Medicine.  The medical assistants 
provided positive feedback that the educational sessions provided were beneficial.  The 
MAs provide the majority of the vaccines to patients in the clinic and are often the first 
line in initiating the recommendation for vaccination.  The providers, while having a 
baseline understanding of the purpose of giving the Tdap during pregnancy, are often so 
busy they might forget to order the vaccine.  Providers who returned surveys all agreed or 
strongly agreed the updated checklist and patient education sheet would be helpful as a 
reminder in practice to order the Tdap vaccine.  Collectively, the intervention was 
successful at increasing the rates of Tdap provided to pregnant women in Greeley, 
Colorado with the overall goal of reducing pertussis rates in the infant population and 
reducing the morbidity and mortality of a vaccine preventable disease. 
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CHAPTER V 
 
 
RECOMMENDATIONS AND IMPLICATIONS  
FOR PRACTICE 
 
 
 North Colorado Family Medicine (NCFM), as a representative of Banner Health 
in the northern region of Colorado, prides itself on providing the most up-to-date and 
evidence-based care to patients and the community.  This project targeted only a small 
and specific population in Northern Colorado but was predicted to have rippling benefits.  
The topic of vaccinations in any population remains a controversial one with patient 
opinions and decisions based on ever-expansive access to the internet.  Despite the 
opinions of some, vaccinations remain one of the single most effective methods of 
disease prevention in the general public.  Data in this project supported individuals 
educated by their healthcare professionals are more likely to agree to be immunized.  
With the culture of health care being focused on prevention, the job of providing 
expansive preventive care rests primarily on the shoulders of primary care providers.  
Projects such as this capstone could help improve outcomes in the primary care setting by 
improving access to and offering reminders for health promotion and disease prevention. 
Recommendations for North Colorado Family Medicine 
 One of the benefits of this project was the ease with which it could be maintained, 
sustained, and applied to the general population.  This project focused on improving well-
established and current practice by revising and improving existing tools used in provider 
practice.  The provider reminder checklist and patient education factsheet are now 
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established and will remain in use after the conclusion of this project.  A further 
recommendation that could improve pregnancy outcomes would be the inclusion of an 
influenza factsheet in the patient packet along with the pertussis factsheet.  This project 
offered other avenues for projects to improve overall vaccine rates and preventive care 
provided to the Greeley community.  Each medical resident is also required to do a 
capstone project at the end of their third year at the clinic, which offers unlimited 
opportunities for process improvement.  With medicine changing at such a fast pace, 
clinics such as NFCM, which are so readily willing to adopt new ideas and/or improve 
current practice, will have better outcomes that will not only affect the patient population 
but the community at large.   
A limitation noted in Chapter IV discussed the outcomes of objective three being 
confounded by the high rate of medical assistant turnover at NCFM.  In the 14-week span 
of time from the initiation of the project, there was a large turnover in MAs at the clinic 
and this rate of turnover is not expected to slow down.  It was determined that a third 
educational session given in the 14week intervention window would have been beneficial 
to cover for the unpredicted turnover that occurred.  In an effort to push for sustainability, 
the educational PowerPoint was provided to the nursing director for future education of 
new MAs.  In discussing this with the nursing director, this high turnover rate is not 
uncommon as this job can often be considered a stepping stone to other roles in health 
care.  Influence on vaccination rates by the MAs at NCFM will require ongoing 
education to the incoming staff by the nursing director, providers, and existing MAs.  It is 
the recommendation of this researcher that the presentation be given quarterly at 
mandatory staff meetings as well as being incorporated into the MA new hire orientation.  
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This will offer reminders to existing staff as well as providing education to any new and 
incoming MAs.   
Possible Applications in Other Settings 
With the ease of sustainability of this project at NCFM, this author believes this 
project can be expanded.  The CDC website has ample educational material available at 
no charge including a toolkit available to all providers for increasing Tdap vaccination 
rates in pregnancy and educational materials for patients, families, and members of the 
community.  Examples of this include posters that can be strategically placed in clinic 
waiting rooms and exam rooms, scripting resources for providers to answer questions 
about the safety and efficacy of the vaccine, and tips for coding immunizations to ensure 
the clinic receives reimbursement for the Tdap vaccine.   
As a member of Banner Health, a large multi-state health system with sites in 
Nebraska, Arizona, Colorado, Alaska, California, Nevada, and Wyoming, this project 
could be disseminated throughout the system to other clinic sites, targeting a wider group 
of pregnant women with the intention of having a greater impact on pertussis rates in the 
western United States.  As discussed in Chapter I, this project aligned with Banner 
Health’s (2016b) strategic plan for providing high quality and excellent care to all of its 
patients.  As of October 2012, best practice in the care of pregnant women is to provide 
the Tdap vaccination between 27 and 36 weeks.  Banner Health’s strategic plan involves 
acting on opportunities and change, constantly improving care, and focusing on 
protecting one of our most vulnerable populations.   
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Contribution to Personal Leadership Goals 
 This researcher sees the role of the Doctor of Nursing Practice (DNP) as having a 
substantial impact on illness prevention and health promotion in the future of health care.  
It was the goal of this DNP candidate to work toward shifting the focus to primary 
prevention in a population health setting.  Projects such as this that target a vulnerable 
population have the ability to have a larger and more substantial impact on the future of 
health care.  It was this researcher’s goal to use the knowledge and experience gained 
through the implementation of this project to implement future population-focused illness 
prevention and health promotion projects in rural settings in need of such expertise.  
Projects such as this one have the ability to expand and grow, leading to a ripple effect 
that has the ability to make a significant impact on the lives of those it affects.  If this 
project prevented even one infant from contracting pertussis, then that impact will have 
made enough of a difference in the lives of individuals otherwise affected.  Thus, this 
researcher’s goal of having a positive impact on the community will have been reached. 
Summary 
 Pertussis is highly contagious and can lead to costly hospitalizations and even 
death in infants less than three months old but is preventable with vaccines.  Available 
literature and research are overwhelmingly in support of the safety and efficacy of the 
Tdap vaccine during pregnancy.  Mothers use their own immune system to create 
antibodies that will protect their infants through the first few months of life and providers 
are in a unique position to improve vaccine rates through education and recommendation.   
 This project targeted individual pregnant patients with the goal of impacting the 
greater community through the reduction of pertussis rates in the population most 
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vulnerable and susceptible to the high rates of morbidity and mortality.  This project used 
a quality improvement process directly aimed at established practices as well as provider 
and patient education to bring about practice improvement.  Vaccines remain one of the 
best tools for improving community and population health.  By circling the wagons 
around infants, families and communities will be strengthened by the outcomes of 
improving immunization rates in pregnant women.  Infants are susceptible to pertussis; it 
is up to parents, providers, and the community at large to offer protection to this 
vulnerable population.   
 
 
66 
 
 
 
 
 
 
REFERENCES 
 
 
Ahluwalia, I. B., Ding, H., D’Angelo, D., Shealy, K. H., Singleton, J. A., Liang, J., & 
Rosenberg, K. D. (2015). Tetanus, diphtheria, pertussis vaccination coverage 
before, during, and after pregnancy-16 states and New York City, 2011. 
Morbidity and Mortality Weekly Report, 64(19), 522-526. Retrieved from 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6419a4.htm 
Allen, A. (2013). Public health. The pertussis paradox. Science, 341, 454-455.  
doi:10.1126/science.341.6145.454  
Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E., Donegan, K., 
...Ramsay, M. (2014). Effectiveness of maternal pertussis vaccination in England: 
An observational study. The Lancet, 384(9953), 1521-1528.   
doi:10.1016/S0140-6736(14)60686-3 
Banner Health. (2016a). At a glance: Our non-profit mission. Retrieved from 
https://www.bannerhealth.com/about/mission 
Banner Health. (2016b). North Colorado family medicine clinic. Retrieved from 
https://www.bannerhealth.com/Physicians+and+Residents/Residency+and+Fello
wship+Programs/_Programs/_North+Colorado+Family+Medicine+Residency/Re
sidency+Applicants/Facilities/NCFM+Clinic.htm 
 
67 
 
Bechini, A., Tiscione, E., Boccalini, S., Levi, M., & Bonanni, P. (2012). Acellular 
pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and 
health care workers): A review of evidences and recommendations. Vaccine, 
30(35), 5179-5190. doi:10.1016/j.vaccine.2012.06.005 
Caro, J. J., Getsios, D., Payne, K., Annemans, L., Neumann, P. J., & Trindade, E. (2005). 
Economic burden of pertussis and the impact of immunization. The Pediatric 
Infectious Disease Journal, 24(5), S48-S54. Retrieved from http://journals.lww. 
com/pidj/Abstract/2005/05001/Economic_Burden_of_Pertussis_and_the_Impact_
of.9.aspx 
Centers for Disease Control and Prevention. (2013a). 2012 final pertussis surveillance 
report [CS244006-A]. Retrieved from http://www.cdc.gov/pertussis/downloads/ 
pertuss-surv-report-2012.pdf 
Centers for Disease Control and Prevention. (2013b). Updated recommendations for use 
of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 
(Tdap) in pregnant women. Morbidity and Mortality Weekly Report, 62(7), 131-
135. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/ 
mm6207a4.htm 
Centers for Disease Control and Prevention. (2014a). 2013 final pertussis surveillance 
report [CS252563A]. Retrieved from http://www.cdc.gov/pertussis/downloads/ 
pertuss-surv-report-2013.pdf 
Centers for Disease Control and Prevention. (2014b). Timeline of adult and adolescent 
recommendations. Retrieved from http://www.cdc.gov/vaccines/vpd-vac/combo-
vaccines/DTaP-Td-DT/Tdap.htm 
68 
 
Centers for Disease Control and Prevention. (2015a). 2014 final pertussis surveillance 
report [CS260514A]. Retrieved from http://www.cdc.gov/pertussis/downloads/ 
pertuss-surv-repot-2014.pdf 
Centers for Disease Control and Prevention. (2015b). You can start protecting your baby 
from whooping cough before birth. Retrieved from http://www.cdc.gov/pertussis/         
downloads/fs-protecting-before-birth.pdf 
Centers for Disease Control and Prevention. (2015c). Whooping cough and the vaccine 
(shot) to prevent it: Fact sheet for parents. Retrieved from http://www.cdc.gov/ 
vaccines/parents/diseases/child/pertussis.html 
Centers for Disease Control and Prevention. (2016). Adult immunization schedule.  
Retrieved from http://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html 
Chamberlain, A. T., Seib, K., Ault, K. A., Orenstein, W. A., Frew, P. M., Malik, F., 
…Omer, S. B. (2015). Factors associated with intention to receive influenza and 
tetanus, diphtheria, and acellular pertussis (Tdap) vaccines during pregnancy: A 
focus on vaccine hesitancy and perceptions of disease severity and vaccine safety. 
Retrieved from http://doi.org/10.1371/currents.outbreaks.d37b61bceebae5a7a 
06d40a301cfa819 
Cherry, J. D. (1996). Historical review of pertussis and the classical vaccine. Journal of 
Infectious Diseases, 174(Supplement 3), S259-S263.  
doi:10.1093/infdis/174.Supplement_3.S259 
Cherry, J. D. (2015). Tetanus-diphtheria-pertussis immunization in pregnant women and 
the prevention of pertussis in young infants. Clinical Infectious Diseases: An 
Official Publication of the Infectious Diseases Society of America, 60(3), 338.  
69 
 
Cornia P., & Lipsky, B. A. (2015). Bordetella pertussis infection: Epidemiology, 
microbiology, and pathogenesis. Retrieved from http://www.uptodate.com/ 
contents/pertussis-infection-epidemiology-microbiology-and-pathogenesis 
Dabrera, G., Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E.. 
…Ramsay, M. (2015). A case-control study to estimate the effectiveness of 
maternal pertussis vaccination in protecting newborn infants in England and 
Wales, 2012-2013. Clinical Infectious Diseases: An Official Publication of the 
Infectious Diseases Society of America, 60(3), 333-337. doi:10.1093/cid/ciu821 
Donaldson, B., Jain, P., Holder, B. S., Lindsay, B., Regan, L., & Kampmann, B. (2015). 
What determines uptake of pertussis vaccine in pregnancy? A cross sectional 
survey in an ethnically diverse population of pregnant women in 
London. Vaccine, 33(43), 5822-5828. doi:10.1016/j.vaccine.2015.08.093 
Forsyth, K., Plotkin, S., Tan, T., & von König, C. H. W. (2015). Strategies to decrease 
pertussis transmission to infants. Retrieved from http://pediatrics. 
aappublications.org/content/early/2015/05/06/peds.2014-3925 
Gaglio, B., Shoup, J. A., & Glasgow, R. E. (2013). The RE-AIM framework: A 
systematic review of use over time. American Journal of Public Health, 103(6), 
e38-e46. doi:10.2105/AJPH.2013.301299 
Glasgow, R. E., Vogt, T. M., & Boles, S. M. (1999). Evaluating the public health impact 
of health promotion interventions: The RE-AIM framework. American Journal of 
Public Health, 89(9), 1322-1327. doi:10.2105/AJPH.89.9.1322 
 
70 
 
Goldfarb, I. T., Little, S., Brown, J., & Riley, L. E. (2014). Use of the combined tetanus-
diphtheria and pertussis vaccine during pregnancy. American Journal of 
Obstetrics and Gynecology, 211(3), 299.e1-299.e5. 
doi:10.1016/j.ajog.2014.05.029 
Greenberg, D. P., & Caro, J. J. (2005). Summary: Health and economic burden of 
pertussis. The Pediatric Infectious Disease Journal, 24(5), S55-S57. Retrieved 
from http://journals.lww.com/pidj/Fulltext/2005/05001/Summary__Health_ 
and_Economic_Burden_of_Pertussis.10.aspx 
Harriman, K., & Winter, K. (2014). Pertussis vaccine uptake during pregnancy: We need 
to do better in the US. Preventive Medicine, 67, 320-321.  
doi:10.1016/j.ypmed.2014.06.015 
Healy, C. M., Ng, N., Taylor, R. S., Rench, M. A., & Swain, L. S. (2015). Tetanus and 
diphtheria toxoids and acellular pertussis vaccine uptake during pregnancy in a 
metropolitan tertiary care center. Vaccine, 33(38), 4983-4987.  
doi:10.1016/j.vaccine.2015.07.018 
Healy, C. M., Rench, M. A., Montesinos, D. P., Ng, N., & Swaim, L. S. (2015). 
Knowledge and attitudes of pregnant women and their providers towards 
recommendations for immunization during pregnancy. Vaccine, 33(41), 5445. 
doi:10.1016/j.vaccine.2015.08.028 
 
 
 
71 
 
Housey, M., Zhang, F., Miller, C., Lyon-Callo, S., McFadden, J., Garcia, E., & Potter, R. 
(2014). Vaccination with tetanus, diphtheria, and acellular pertussis vaccine of 
pregnant women enrolled in Medicaid-Michigan, 2011-2013. Morbidity and 
Mortality Weekly Report, 63(38), 839–842. Retrieved from http://www.cdc.gov/ 
mmwr/preview/mmwrhtml/mm6338a4.htm 
Huygen, K., Caboré, R. N., Maertens, K., Van Damme, P., & Leuridan, E. (2015). 
Humoral and cell mediated immune responses to a pertussis containing vaccine in 
pregnant and nonpregnant women. Vaccine, 33(33), 4117. 
doi:10.1016/j.vaccine.2015.06.108 
Keller-Stanislawski, B., Englund, J. A., Kang, G., Mangtani, P., Neuzil, K., Nohynek, H., 
…Zuber, P. (2014). Safety of immunization during pregnancy: A review of the 
evidence of selected inactivated and live attenuated vaccines. Vaccine, 32(52), 
7057-7064. doi:10.1016/j.vaccine.2014.09.052 
Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Klein, N. P., Cheetham, T. C., 
Naleway, A., …Nordin, J. D. (2014). Evaluation of the association of maternal 
pertussis vaccination with obstetric events and birth outcomes. JAMA, 312(18), 
1897-1904. doi:10.1001/jama.2014.1482 
Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Klein, N. P., Cheetham, T. C., 
Naleway, A. L., …Nordin, J. D. (2016). Maternal Tdap vaccination: Coverage 
and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine, 
34(7), 968. doi:10.1016/j.vaccine.2015.12.046 
 
72 
 
Larson, H. J., Jarrett, C., Schulz, W. S., Chaudhuri, M., Zhou, Y., Dube, E., …SAGE 
Working Group on Vaccine Hesitancy. (2015). Measuring vaccine hesitancy: The 
development of a survey tool. Vaccine, 33(34), 4165. 
doi:10.1016/j.vaccine.2015.04.037 
Lugnér, A. K., van der Maas, N., van Boven, M., Mooi, F. R., & de Melker, H. E. (2013). 
Cost-effectiveness of targeted vaccination to protect newborns against pertussis: 
Comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine, 
31(46), 5392-5397. doi:10.1016/j.vaccine.2013.09.028 
Morgan, J. L., Baggari, S. R., Chung, W., Ritch, J., McIntire, D. D., & Sheffield, J. S. 
(2015). Association of a best-practice alert and prenatal administration with 
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination 
rates. Obstetrics and Gynecology, 126(2), 333-337. 
doi:10.1097/AOG.0000000000000975 
Munoz, F. M., Bond, N. H., Maccato, M., Pinell, P., Hammill, H. A., Swamy, G. K., 
…Baker, C. J. (2014). Safety and immunogenicity of tetanus diphtheria and 
acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: 
A randomized clinical trial. JAMA, 311(17), 1760-1769. 
doi:10.1001/jama.2014.3633 
National Foundation for Infectious Diseases. (2014). Call to action--Improving 
vaccination rates in pregnant women: Timely intervention-lasting benefits. 
Retrieved from http://www.nfid.org/homepage/additional-offerings/ 
Nesin, M., Read, J., Koso-Thomas, M., Isaacs, M. B., & Meulen, A. S. (2015). Maternal 
immunization: Current status and future prospects. Vaccine, 33(47), 6371.  
73 
 
Nitsch-Osuch, A., Korzeniewski, K., Gawlak, M., Życińska, K., Wardyn, K., & Kuchar, 
E. (2014). Epidemiological and clinical reasons for vaccination against pertussis 
and influenza in pregnant women. In Environmental biomedicine (pp. 11-21). 
New York: Springer International Publishing. doi: 10.1007/5584_2014_95 
O'Brien, J. A., & Caro, J. J. (2005). Hospitalization for pertussis: Profiles and case costs 
by age. BMC Infectious Diseases, 5(1), 57-57. doi:10.1186/1471-2334-5-57 
Payakachat, N., Hadden, K. B., & Ragland, D. (2016). Promoting tdap immunization in 
pregnancy: Associations between maternal perceptions and vaccination rates. 
Vaccine, 34(1), 179-186. doi:10.1016/j.vaccine.2015.09.062 
Planas, L. G. (2008). Intervention design, implementation, and evaluation. American 
Journal of Health-System Pharmacy, 65(19), 1854-1863. doi:10.2146/ajhp070366 
Raya, B. A., Bamberger, E., Almog, M., Peri, R., Srugo, I., & Kessel, A. (2015). 
Immunization of pregnant women against pertussis: The effect of timing on 
antibody avidity. Vaccine, 33(16), 1948-1952. doi:10.1016/j.vaccine.2015.02.059 
Raya, B. A., Srugo, I., Kessel, A., Peterman, M., Bader, D., Gonen, R., & Bamberger, E. 
(2014). The effect of timing of maternal tetanus, diphtheria, and acellular 
pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody 
levels–A prospective study. Vaccine, 32(44), 5787-5793.  
doi: 10.1016/j.vaccine.2014.08.038 
Raya, B. A., Srugo, I., Kessel, A., Peterman, M., Bader, D., Peri, R., ...Bamberger, E. 
(2014). The induction of breast milk pertussis specific antibodies following 
gestational tetanus–diphtheria–acellular pertussis vaccination. Vaccine, 32(43), 
5632-5637. doi:10.1016/j.vaccine.2014.2014.08.006 
74 
 
Raya, B., Srugo, I., Kessel, A., Peterman, M., Vaknin, A., & Bamberger, E. (2015). The 
decline of pertussis-specific antibodies after tetanus, diphtheria, and acellular 
pertussis immunization in late pregnancy. The Journal of Infectious 
Diseases, 212(12), 1869 
Sawyer, M. H., & Long, S. S. (2015). Tdap in every pregnancy: Circling the wagons 
around the newborn. Pediatrics, 135(6), e1483-e1484.  
doi:10.1542/peds.2015-0770 
Shakib, J. H., Korgenski, K., Sheng, X., Varner, M. W., Pavia, A. T., & Byington, C. L. 
(2013). Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: 
Pregnancy and infant health outcomes. The Journal of Pediatrics,163(5), 1422-
1426.e4. doi:10.1016/j.jpeds.2013.06.021 
Terranella, A., Asay, G. R. B., Messonnier, M. L., Clark, T. A., & Liang, J. L. (2013). 
Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: A 
decision analysis. Pediatrics, 131(6), e1748.  doi:10.1542/peds.2012-3144 
Vilajeliu, A., Goncé, A., López, M., Costa, J., Rocamora, L., Ríos, J., ...PERTU Working 
Group. (2015). Combined tetanus-diphtheria and pertussis vaccine during 
pregnancy: Transfer of maternal pertussis antibodies to the newborn. Vaccine, 
33(8), 1056-1062. 
Virginia Tech. (2015). Reach, effectiveness, adoption, implementation, & maintenance 
(RE-AIM). Retrieved from http://www.re-aim.hnfe.vt.edu/about_re-
aim/index.html 
75 
 
Wilson, R. J., Paterson, P., Jarrett, C., & Larson, H. J. (2015). Understanding factors 
influencing vaccination acceptance during pregnancy globally: A literature 
review. Vaccine, 33(47), 6420-6429. doi:10.1016/j.vaccine.2015.08.046 
Yeh, S. (2016). Bordetella pertussis infection in infants and children: Treatment and 
prevention. Retrieved from http://www.uptodate.com/contents/pertussis-infection-
in-infants-and-children-treatment-and-prevention 
Yeh, S., & Mink, C. M. (2016). Bordetella pertussis infection in infants and children: 
Clinical features and diagnosis. Retrieved from http://www.uptodate.com/ 
contents/pertussis-infection-in-infants-and-children-clinical-features-and-
diagnosis 
 
 
 
76 
 
 
 
 
 
 
 
 
 
APPENDIX A 
PROVIDER REMINDER TOOL CURRENTLY USED  
IN PRACTICE 
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Prenatal care highlights 
 
Initial visit from 5-11 weeks: 
Labs including CBC, Hep B, HIV, RPR, Blood type/Rh, urine culture, STI 
Medical history 
Obstetric history including # deliveries and types, PPH, DM, complications 
Establish an idea of pregnancy risk 
Ge early U/S for dating (not the pregnancy resource center) 
Education/community referrals 
Next visit is OB PE; 
Pap if indicated 
STI 
 
Second Trimester:  
Quad screen at 16-19 weeks.  Sometimes needs to be recalculated based on EDC 
Dating u/s if not done already 
U/S for anatomy at 19-22 weeks  
Referral to MFM if determined high risk (quad screen should be done first) 
Fetal movement 
Immunizations 
 
Third Trimester: 
26 weeks: glucose screen; 1 hour to be done on high-risk patients 
28-28 weeks: Rhogam if needed; recommended to repeat Ab screen 
32 weeks:  h/h for anemia and treat if necessary 
34 weeks: Consider repeat 3 hour GTT if the first was mildly abnormal 
Tubal papers if appropriate 
37 weeks: GBS to be done if not already positive 
NST as indicated: DM, GDM, post-dates, IUGR etc. 
 
Other things to consider: 
*When a positive Chlamydia is obtained anytime, a repeat test of cure needs to be done 
four weeks later 
*GBS is good for five weeks; you may need to repeat it if your patient goes post-dates 
*Trace to 1+ protein during the pregnancy is likely related to dehydration and does not 
need a work-up 
*In patient with a history of genital herpes, recommend prophylactic treatment starting 
about 36 weeks to decrease the chance of outbreak at time of delivery. 
*If patient is high risk for HIV (eg; hx of drug abuse), then recommend a repeat HIV to 
be done at 36 weeks. 
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APPENDIX B 
UPDATED PROVIDER REMINDER TOOL TO INCLUDE  
TETANUS, DIPHTHERIA, ACELLULAR PERTUSSIS  
VACCINATION 
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Prenatal care highlights 
 
Initial visit from 5-11 weeks: 
o Labs including CBC, Hep B, HIV, RPR, Blood type/Rh, urine culture, STI 
o Medical history 
o Obstetric history including # deliveries and types, PPH, DM, complications 
o Establish an idea of pregnancy risk 
o Ge early U/S for dating (not the pregnancy resource center) 
o Education/community referrals 
 
Next visit is OB physicial 
o Pap if indicated 
o STI 
 
Second Trimester:  
o Quad screen at 16-19 weeks.  Sometimes needs to be recalculated based on EDC 
o Dating U/S if not done already 
o U/S for anatomy at 19-22 weeks  
o Referral to MFM if determined high risk (quad screen should be done first) 
o Fetal movement 
 
**IMMUNIZATIONS** 
 Influenza Vaccine given anytime in pregnancy during flu season 
 Tdap vaccine given 27-36 weeks despite previous vaccine status 
 
Third Trimester: 
o 26 weeks: glucose screen; 1 hour to be done on high-risk patients 
o 28-28 weeks: Rhogam if needed; recommended to repeat Ab screen 
o 32 weeks:  h/h for anemia and treat if necessary 
o 34 weeks: Consider repeat 3 hour GTT if the first was mildly abnormal 
o Tubal papers if appropriate 
o 37 weeks: GBS to be done if not already positive 
o NST as indicated: DM, GDM, post-dates, IUGR etc. 
 
Other things to consider: 
 When a positive Chlamydia is obtained anytime, a repeat test of cure needs to be done 
four weeks later 
 GBS is good for five weeks; you may need to repeat it if your patient goes post-dates 
 Trace to 1+ protein during the pregnancy is likely related to dehydration and does not 
need a work-up 
 In patient with a history of genital herpes, recommend prophylactic treatment starting 
about 36 weeks to decrease the chance of outbreak at time of delivery. 
 If patient is high risk for HIV (eg hx of drug use), then recommend a repeat HIV to be 
done at 36 weeks. 
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APPENDIX C 
CENTERS FOR DISEASE CONTROL AND PREVENTION  
PATIENT EDUCATIONAL MATERIAL 
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APPENDIX D 
STANDING ORDER FOR ADULTS AND ADOLESCENTS 
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APPENDIX E 
ADULT VACCINATION SCHEDULE 
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APPENDIX F 
POWERPOINT EDUCATION FOR MEDICAL ASSISTANTS 
  
93 
 
 
 
 
94 
 
 
 
 
 
 
95 
 
 
 
 
 
 
  
96 
 
 
 
 
 
 
 
 
APPENDIX G 
STATEMENT OF MUTUAL AGREEMENT 
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APPENDIX H 
INSTITUTIONAL REVIEW BOARD APPROVAL 
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APPENDIX I 
LETTER TO PROVIDERS  
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APPENDIX J 
PROVIDER AND MEDICAL ASSISTANT SURVEYS 
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CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH 
UNIVERSITY OF NORTHERN COLORADO 
 
Project Title: Working towards Tdap in Every Pregnancy:  Protecting Our Most 
Vulnerable Population 
Researchers: Jessica M. Scott (BSN-DNP Student), School of Nursing 
e-mail: mayh3489@bears.unco.edu 
 
The aim of this process improvement project is to improve Tdap rates in pregnant 
patients at North Colorado Family Medicine.  This project is targeted at increasing the 
rates of provider recommendations for Tdap immunizations during pregnancy.  This 
project will include two components that target providers:  1) an update to the prenatal 
highlights provider reminder tool that is located in the OB chart, and 2) a CDC authored 
factsheet on the safety and efficacy of the Tdap vaccine in pregnancy that will be placed 
in the patient education packet to be handed out at the OB intake visit.  
 
All surveys will be distributed to provider clinic mailboxes and will be returned to the 
Dottie Schulte’s clinic mailbox upon completion. It is anticipated that it will take you 
approximately 2-3 minutes to complete the survey.   
 
The purpose of this survey is to evaluate the effectiveness of the updated prenatal 
highlights tool to include a reminder for Tdap immunization in pregnancy, and the 
addition of a CDC authored Tdap in pregnancy factsheet into the OB intake education 
packet as reminder tools for providers to make the recommendation for Tdap in every 
pregnant patient at North Colorado Family Medicine.  Participation is voluntary and 
your responses will be anonymous.  There are no foreseeable risks to participants, as this 
is a process improvement project of a current program already in place and is based on 
national vaccine recommendations. Participants may benefit directly from this project by 
ensuring that best practice is followed based on national recommendations to vaccinate 
every pregnant patient with the Tdap vaccine between 27 and 36 weeks.  
 
Participation is voluntary. You may decide not to participate in this study and if you begin 
participation you may still decide to stop and withdraw at any time. Your decision will be 
respected and will not result in loss of benefits to which you are otherwise entitled. 
Having read the above and having had an opportunity to ask any questions, please access 
and complete the attached document “Improving Tdap Rates in Pregnancy: Provider 
107 
 
Survey”.  Return completed surveys to Dottie Schulte’s mailbox. If at any time you have 
any questions please contact one of the undersigned.   By completing the questionnaire, 
you will give us permission for your participation.  You may keep this form for future 
reference. If you have any concerns about your selection or treatment as a research 
participant, please contact Sherry May, IRB Administrator, Office of Sponsored 
Programs, Kepner Hall, University of Northern Colorado Greeley, CO  80639; 970-351-
1910. 
 
Dottie Schulte FNP-BC   Jessica Scott, DNP (c), RN, BSN 
dottie.schulte@bannerhealth.com   mayh3489@bears.unco.edu 
970-810-2710         
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Improving Tdap Rates in Pregnancy 
Provider Survey 
 
Updated Provider Reminder Tool  
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
This tool will be useful in reminding 
you to facilitate the administration of 
the Tdap vaccine in every pregnant 
patient at 27-36 weeks   
 
1 
 
2 
 
3 
 
4 
 
5 
This updated tool will be beneficial in 
current practice 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
CDC Patient Educational Material 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
The Tdap in pregnancy educational 
material reminded you to discuss the 
vaccine with your patients during the 
OB intake 
 
1 
 
2 
 
3 
 
4 
 
5 
This educational material will be 
beneficial in current practice 
 
1 
 
2 
 
3 
 
4 
 
5 
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CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH 
UNIVERSITY OF NORTHERN COLORADO 
 
Project Title: Working towards Tdap in Every Pregnancy:  Protecting Our Most 
Vulnerable Population 
Researchers: Jessica M. Scott (BSN-DNP Student), School of Nursing 
e-mail: mayh3489@bears.unco.edu 
 
The aim of this process improvement project is to improve Tdap rates in pregnant 
patients at North Colorado Family Medicine.  This project is targeted at increasing the 
rates of Tdap immunizations during pregnancy by empowering Medical Assistants to 
initiate the immunization process.  At the end of the education session(s), the Medical 
Assistants will be able to verbalize the purpose of the Tdap vaccine during pregnancy, the 
window of pregnancy in which the immunization can be given (27-36 weeks), and the 
process if a patient or family member should decline the vaccine.  This project will target 
Medical Assistants at North Colorado Family Medicine through education provided at 
regularly scheduled monthly staff meetings. 
 
All surveys will be distributed to individual Medical Assistant clinic mailboxes and will 
be returned to the Dottie Schulte’s clinic mailbox upon completion. It is anticipated that it 
will take you approximately 2-3 minutes to complete the survey.   
 
The purpose of this survey is to evaluate the effectiveness of the education provided to 
Medical Assistants regarding the purpose and process of administering the Tdap 
immunization in every pregnant patient at North Colorado Family Medicine between 27 
and 36 weeks, and if the vaccine should be declined, deferring education back to the 
provider to offer additional education, and make further recommendations.  Participation 
is voluntary and your responses will be anonymous.  There are no foreseeable risks to 
participants, as this is a process improvement project of a current program already in 
place and is based on national vaccine recommendations. Participants may benefit 
directly from this project by ensuring that best practice is followed based on national 
recommendations to vaccinate every pregnant patient with the Tdap vaccine between 27 
and 36 weeks.  
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Participation is voluntary. You may decide not to participate in this study and if you begin 
participation you may still decide to stop and withdraw at any time. Your decision will be 
respected and will not result in loss of benefits to which you are otherwise entitled. 
Having read the above and having had an opportunity to ask any questions, please access 
and complete the attached document “Improving Tdap Rates in Pregnancy: Provider 
Survey”.  Return completed surveys to Dottie Schulte’s mailbox. If at any time you have 
any questions please contact one of the undersigned.   By completing the questionnaire, 
you will give us permission for your participation.  You may keep this form for future 
reference. If you have any concerns about your selection or treatment as a research 
participant, please contact Sherry May, IRB Administrator, Office of Sponsored 
Programs, Kepner Hall, University of Northern Colorado Greeley, CO  80639; 970-351-
1910. 
 
Dottie Schulte FNP-BC     Jessica Scott, DNP (c), RN, BSN 
dottie.schulte@bannerhealth.com    mayh3489@bears.unco.edu 
970-810-2710        
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Medical Assistant Survey 
Medical Assistant Educational Session 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
Prior to the educational session you 
were aware that it is within the scope of 
your practice to initiate the Tdap 
vaccine in all pregnant women between 
27 and 36 weeks 
 
1 
 
2 
 
3 
 
4 
 
5 
After the educational session provided, 
you will now initiate Tdap vaccine to 
every pregnant woman between 27 and 
36 weeks 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
If a patient refuses the Tdap vaccine, 
you will defer this refusal to the 
patient’s provider to provide additional 
education about the vaccine 
 
 
1 
 
 
2 
 
 
3 
 
 
 
 
4 
 
 
5 
 
 
 
